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Abstract
In the U.S., donor lungs are allocated to recipients based on a lung allocation score (LAS). While the
statistical models used to construct the LAS control for patients’ demographic and clinical values, they do
not account for selection bias, which arises because: (1) individuals are removed from the waitlist once
they receive transplant (dependent censoring), and (2) in order to receive transplant, individuals must
survive on the waitlist long enough for a suitable lung to become available (survivor bias). Failure to
account for selection bias can lead to inaccurate predicted probabilities and suboptimal organ allocation.
The goal of this dissertation is to improve the predictive accuracy of the LAS by mitigating selection bias
so that lungs are allocated to the appropriate patients in the appropriate order. This goal was
accomplished via three aims. First, we proposed a weighted estimation strategy to mitigate selection bias
in the pre- and post-transplant LAS models, constructed a modified LAS score using these weights, and
compared its performance to that of the existing LAS. Second, we examined the clinical impact of our
modified LAS in both observed data and through simulations. Third, we conducted qualitative semistructured interviews with lung transplant surgeons and pulmonologists throughout the U.S. to examine
respondents’ understanding of selection bias and how it may affect the LAS and organ distribution. We
found that our modified LAS exhibited better discrimination and calibration than the existing LAS and led
to changes in patient prioritization. Diagnosis group, six-minute walk distance, continuous mechanical
ventilation, functional status, and age exhibited the largest impact on prioritization changes. Simulations
suggest that one-year waitlist survival may improve under the modified LAS, while one-year posttransplant and overall survival remain comparable to that under the existing LAS. Finally, our qualitative
study demonstrates that selection bias can arise at several points along the transplantation pathway. To
address such bias, transplant centers must consider both patient health and program health within
constraints imposed by donor organ scarcity. We hope that this work can inform future revisions of the
LAS and other prediction models in organ transplantation to ensure more equitable allocation of donor
organs.
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ABSTRACT
SELECTION BIAS IN LUNG ALLOCATION: INFLUENCE ON LUNG ALLOCATION SCORE AND
PHYSICIAN DECISION-MAKING
Erin M. Schnellinger
Stephen E. Kimmel
Alisa J. Stephens-Shields

In the U.S., donor lungs are allocated to recipients based on a lung allocation score (LAS). While
the statistical models used to construct the LAS control for patients’ demographic and clinical
values, they do not account for selection bias, which arises because: (1) individuals are removed
from the waitlist once they receive transplant (dependent censoring), and (2) in order to receive
transplant, individuals must survive on the waitlist long enough for a suitable lung to become
available (survivor bias). Failure to account for selection bias can lead to inaccurate predicted
probabilities and suboptimal organ allocation. The goal of this dissertation is to improve the
predictive accuracy of the LAS by mitigating selection bias so that lungs are allocated to the
appropriate patients in the appropriate order. This goal was accomplished via three aims. First,
we proposed a weighted estimation strategy to mitigate selection bias in the pre- and posttransplant LAS models, constructed a modified LAS score using these weights, and compared its
performance to that of the existing LAS. Second, we examined the clinical impact of our modified
LAS in both observed data and through simulations. Third, we conducted qualitative semistructured interviews with lung transplant surgeons and pulmonologists throughout the U.S. to
examine respondents’ understanding of selection bias and how it may affect the LAS and organ
distribution. We found that our modified LAS exhibited better discrimination and calibration than
the existing LAS and led to changes in patient prioritization. Diagnosis group, six-minute walk
distance, continuous mechanical ventilation, functional status, and age exhibited the largest
impact on prioritization changes. Simulations suggest that one-year waitlist survival may improve
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under the modified LAS, while one-year post-transplant and overall survival remain comparable to
that under the existing LAS. Finally, our qualitative study demonstrates that selection bias can
arise at several points along the transplantation pathway. To address such bias, transplant
centers must consider both patient health and program health within constraints imposed by
donor organ scarcity. We hope that this work can inform future revisions of the LAS and other
prediction models in organ transplantation to ensure more equitable allocation of donor organs.
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CHAPTER 1. INTRODUCTION

Dissertation Overview
In May 2005, the Organ Procurement and Transplantation Network (OPTN)
modified their lung transplantation policy from one in which potential recipients were
prioritized based on the amount of time spent on the waitlist, to one in which donor lungs
were allocated to recipients based on a lung allocation score (LAS) (Egan et al., 2006;
Gottlieb, 2017; U.S. Department of Health and Human Services, October 20, 1999;
United Network for Organ Sharing, 2015). The LAS is calculated as the difference in
predicted days of life between transplant benefit (post-transplant survival minus pretransplant survival) and waitlist urgency (pre-transplant survival) and is normalized so
that it ranges from 0 to 100, with higher values indicating greater priority for lung
transplantation (Egan et al., 2006; United Network for Organ Sharing, 2015). This score
was intended to balance equity, justice, beneficence, and utility in lung allocation
(Gottlieb, 2017; Veatch & Ross, 2015). Since the adoption of the LAS, studies have
shown that the mortality rate for patients on the lung transplant waitlist has decreased; a
greater proportion of transplants have been performed for patients with pulmonary
fibrosis compared to patients with other diagnoses; older and sicker patients are being
transplanted at a higher rate; and one-year post-transplant survival has not changed
significantly (Chen et al., 2009; Gries et al., 2007; Kotloff, 2013; Kozower et al., 2008;
Lingaraju et al., 2006; McCue et al., 2008; Merlo et al., 2009). However, other studies
have suggested that the LAS is “broken,” (Halpern, 2015) as its implementation is
associated with greater resource use (Maxwell et al., 2015) and geographic and gender
disparities in lung allocation (Russo et al., 2013; Thabut et al., 2012; Wille et al., 2013).
A limitation of the LAS score is that the prediction of post-transplant survival that
1

is used in the score is limited to those who survive to transplant. Although the statistical
models used to estimate transplant benefit and waitlist urgency control for patient
characteristics, they do not account for the fact that in order to receive a lung transplant,
an individual must survive on the waitlist long enough for a suitable donor lung to
become available. Since individuals who survive one year or more on the waitlist might
be inherently different from individuals who die, receive a transplant, or are censored
prior to one year, selection bias can arise. Failure to incorporate such information in the
models used to estimate transplant benefit and waitlist urgency can lead to inaccurate
LAS predictions.
The goal of this dissertation is to improve the predictive accuracy of the LAS by
mitigating selection bias so that lungs are allocated to the appropriate patients in the
appropriate order. We undertook both quantitative and qualitative aims to achieve this
goal. Quantitatively, we aim to mitigate selection bias in the LAS and improve its
predictive accuracy. To do so, we build upon recent methodological research reported in
both the transplant and causal inference literature that has begun to incorporate the
problem of dependent censoring into the calculation of transplant benefit and waitlist
urgency (Tayob & Murray, 2017; Vock et al., 2017; Vock et al., 2013; Xiang & Murray,
2012; Xiang et al., 2014). Qualitatively, we aim to understand how clinicians perceive
and use information from the LAS in their decision-making processes. To do so, we
conduct qualitative interviews with lung transplant surgeons and pulmonologists
throughout the United States to determine how these clinicians use the LAS in practice,
how they think about selection and survivor bias in lung allocation, and whether they feel
the LAS should be modified to account for such biases.

2

Background and Significance
Lung Allocation in the United States
The use of lung transplantation as a treatment for end-stage lung diseases has
become increasingly common in the United States, with over 2,000 lung transplants
being performed each year (U.S. Department of Health & Human Services, 2018).
However, waitlist mortality is still quite high (by age, it varied from 14.4 to 28.4 deaths
per 100 waitlist years in 2018, the most recent year for which data were available), and
waiting times vary depending on patients’ diagnoses (U.S. Department of Health &
Human Services, 2018). In fact, concerns about inequities in waitlist mortality among
different types of patients led the Organ Procurement and Transplantation Network
(OPTN) to adopt the Department of Health and Human Service’s “Final Rule” in 2005.
This Rule mandated the development of a new lung allocation system based on “medical
urgency” rather than wait time (U.S. Department of Health and Human Services October
20, 1999).
Today, donor lungs are allocated to potential recipients via the LAS, which
prioritizes patients based on a combination of estimated waitlist urgency and transplant
benefit so that equity and utility can be maximized (Gottlieb, 2017; Veatch & Ross,
2015). More specifically, the LAS relies on clinical factors – such as demographic and
laboratory values – to predict waitlist and post-transplant survival. These predictions are
then used to estimate the number of days of life a person would gain over the next year
if they receive transplant compared to if they do not receive transplant. Patients for
whom this comparison is more favorable receive higher priority for transplant.

3

Performance of the LAS
Studies of LAS performance raise concerns about the accuracy of the predicted
pre- and post-transplant survival components of the score. In a study of the relationship
between transplant candidates’ LAS scores and their pre- and post-transplant outcomes,
Russo et al. questioned why 77% of lower-priority patients (i.e., patients with LAS scores
between 40 and 49) undergo transplantation, whereas only 45% of higher-priority
patients (i.e., patients with LAS scores of 80 or more) receive transplants (Russo et al.,
2011), even though lower-priority candidates typically experience less survival benefit
from transplant compared to higher-priority candidates. Perhaps more concerningly,
Gries et al.’s attempt to develop and validate a predictive model for 5-year survival after
lung transplantation yielded extremely low measures of predictive ability (e.g., areas
under the receiver operating characteristic curve between 0.553 and 0.591) (Gries et al.,
2010). Each of these studies suggest that the LAS has a serious problem: it does not
adequately predict survival. Consequently, individuals are prioritized inappropriately,
which, in turn, leads to inequitable allocation of donor lungs (Halpern, 2015; Maxwell et
al., 2015; Russo et al., 2013; Thabut et al., 2012; Wille et al., 2013).

Updates to LAS Coefficients and Selection Bias
Although the coefficients of the LAS were updated in 2010 and 2015 by refitting
the model using a more recent cohort of patients, the problems discussed above have
persisted, as is evident by the most recent OPTN report (U.S. Department of Health &
Human Services, 2018). One reason why re-estimation of LAS coefficients via model
refitting is insufficient to alleviate these disparities is that this approach does not fully
account for selection bias. Selection bias arises due to 1) dependent censoring
4

(Egleston et al., 2007; Freiman & Small, 2014; Wang et al., 2017): individuals are
removed from the waitlist upon receipt of transplant; and 2) survivor bias (Glymour &
Greenland, 2008): individuals must survive long enough in order to receive transplant.
Failing to account for selection bias can lead to inaccurate predicted probabilities and
suboptimal organ allocation. As an example, naïvely considering post-transplant survival
probability only among individuals who survive on the waitlist might lead to the
conclusion that a patient with a lower risk of dying on the waitlist is a better candidate for
transplant than a patient with a higher risk of dying on the waitlist, even though the latter
patient might actually experience a greater benefit from transplant than the former.

Causal Inference and Potential Outcomes
The “potential outcomes” framework allows us to address the selection bias issue
by conceptualizing it in terms of counterfactual outcomes. Utilized extensively in the
causal inference field, the “potential outcomes” framework defines individual causal
effects as the difference (or ratio) of potential outcomes that would have been observed
for a given individual under different exposure levels (Little & Rubin, 2000). Since only
one potential outcome will be observed for any particular individual – namely, the
outcome that resulted under the level of exposure that the individual actually
experienced (Little & Rubin, 2000) – we cannot estimate individual causal effects using
observed data. However, under assumptions, we can estimate an average causal effect
across a well-defined population. Thus, application of the potential outcome framework
to our problem requires identification of the population of interest. Here, we are
interested in making inference about all individuals registered on the UNOS waitlist. That
is, patients become eligible for our analysis with waitlist registration. Within this
population, the target quantity is defined as the estimated survival benefit patients would
5

accrue if they received a transplant, compared to what they would experience had they
not received a transplant (but remained on the waitlist). Individuals who die, are removed
from the waitlist, or are otherwise lost to follow-up prior to transplantation are censored
from our analyses. In Chapters 2 and 3, we incorporate these causal inference principles
into existing prediction model frameworks to develop and evaluate an improved LAS
algorithm.

Clinician Decision-Making and the LAS
When deciding whether to pursue lung transplantation, clinicians must determine
whether the “potential benefits of transplant outweigh the potential risks and harms”
(Yusen, 2009). The LAS ostensibly performs this comparison by comparing patients’
predicted survival with versus without transplant and allocating organs to those for whom
this comparison is more favorable. However, additional factors beyond the LAS can
impact which patients are selected for – and ultimately receive – transplant, including the
timing of referral (Weill et al., 2015) and geographic, gender, or racial/ethnic disparities
in waitlist registration (Mooney et al., 2018; Ross-Driscoll et al., 2020; Thabut et al.,
2012; Wille et al., 2013), pre- and post-transplant survival (Egan & Edwards, 2016;
Maxwell et al., 2014; Russo et al., 2011), and donor organ availability (Benvenuto et al.,
2018; Drolen et al., 2020; Ross-Driscoll et al., 2020). These factors can exacerbate the
selection bias problem detailed above. For example, individuals who are referred to a
transplant center too early or too late (Mooney et al., 2019; Ramos et al., 2019;
Stephenson et al., 2021), or who seem (from the perspective of transplant clinicians) to
have poor social and/or financial support (Blumenthal et al., 2017; Ladin et al., 2019),
may not be registered on the waitlist, despite the fact that they could, in fact, benefit from
transplant.
6

Although much statistical research has been conducted surrounding the LAS and
selection bias (Vock et al., 2017; Vock et al., 2013; Xiang & Murray, 2012; Xiang et al.,
2014), it is unclear how clinicians employ the LAS in their decision-making processes,
and how they interpret and respond to selection bias. To date, qualitative studies in this
space tended to restrict their focus to one specific aspect of the transplantation process
(e.g., screening/evaluation (Blumenthal et al., 2017; Volk et al., 2011) or donor organ
acceptance (Loss et al., 2013)) at the exclusion of other steps; emphasized patient-level
selection factors rather than program-level factors (Blumenthal et al., 2017); and ignored
how patients’ LAS scores (or, for liver transplant candidates, Model for End Stage Liver
Disease [MELD] scores) might influence candidate selection (Blumenthal et al., 2017;
Volk et al., 2011).
Given that OPTN is currently developing a new organ allocation framework – the
continuous distribution model (Kasiske et al., 2020; Snyder et al., 2018; U.S. Department
of Health & Human Services) – and that this new framework is planned to be
implemented in lung transplant selection, followed by other organs (e.g., kidney, liver,
heart), it is important to develop a thorough understanding of where selection bias can
arise in the current lung allocation system and how such biases can impact the success
and fairness of lung allocation. Toward that end, in Chapter 4, we conducted a
qualitative study of lung transplant surgeons and pulmonologists to understand the role
that the LAS plays in clinical decision making, how transplant clinicians think about
selection and survivor bias in lung allocation, and whether they feel the LAS should be
modified to account for such biases. Studying these questions qualitatively can help
inform the findings of our quantitative aims in the context of clinical practice and can
generate hypotheses for future research.
7

Dissertation Aims
This dissertation is comprised of both quantitative and qualitative aims. The
quantitative aim is to modify the LAS algorithm to account for selection bias and
compare the performance of the modified and existing LAS. The qualitative aim is to
understand the role that the LAS plays in clinical decision making. These two aims are
accomplished through three separate analyses, which are thematically linked by the
notion of selection bias and how it is a concern in lung transplantation.
In Chapter 2, we propose a weighted estimation strategy to mitigate selection
bias in the pre- and post-transplant LAS models. We then compare the predictive
performance of the modified and existing LAS models by 1) evaluating discrimination
and calibration, and 2) comparing patient rankings and predicted survival. In Chapter 3,
we examine the clinical impact of our modified LAS developed in Chapter 2. More
specifically, we use observed data to investigate the demographic and clinical
characteristics of patients who receive higher or lower priority under the modified LAS
relative to the existing one. We also conduct a statistical simulation study to evaluate
how the modified LAS might impact waitlist and post-transplant survival if it were
implemented in clinical practice. In Chapter 4, we conduct semi-structured interviews
with lung transplant surgeons and pulmonologists throughout the United States to
examine respondents’ understanding of selection bias and how it is a concern in lung
transplantation and the LAS. In Chapter 5, we provide concluding remarks and suggest
potential avenues for future research.

8

CHAPTER 2. MITIGATING SELECTION BIAS IN ORGAN ALLOCATION MODELS

This chapter has been published in BMC Medical Research Methodology, and is reprinted here
with permission. Copyright © The Author(s) 2021. The citation for this publication is:
Schnellinger EM, Cantu E, Harhay MO, Schaubel DE, Kimmel SE, Stephens-Shields AJ. Mitigating
Selection Bias in Organ Allocation Models. BMC Medical Research Methodology 2021; 21: 191.
doi: https://doi.org/10.1186/s12874-021-01379-7.
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Abstract
Background. The lung allocation system in the U.S. prioritizes lung transplant
candidates based on estimated pre- and post-transplant survival via the Lung Allocation
Scores (LAS). However, these models do not account for selection bias, which results
from individuals being removed from the waitlist due to receipt of transplant, as well as
transplanted individuals necessarily having survived long enough to receive a transplant.
Such selection biases lead to inaccurate predictions.
Methods. We used a weighted estimation strategy to account for selection bias in the
pre- and post-transplant models used to calculate the LAS. We then created a modified
LAS using these weights, and compared its performance to that of the existing LAS via
time-dependent receiver operating characteristic (ROC) curves, calibration curves, and
Bland-Altman plots.
Results. The modified LAS exhibited better discrimination and calibration than the
existing LAS, and led to changes in patient prioritization.
Conclusions. Our approach to addressing selection bias is intuitive and can be applied
to any organ allocation system that prioritizes patients based on estimated pre- and
post-transplant survival. This work is especially relevant to current efforts to ensure more
equitable distribution of organs.

10

Background
The Organ Procurement and Transplantation Network (OPTN) is responsible for
allocating deceased-donor organs in the United States. The OPTN utilizes separate
policies to govern the allocation of livers, kidneys, hearts, and lungs (Organ Procurement
and Transplantation Network, 2020). For example, liver transplant candidates receive a
Model for End-Stage Liver Disease (MELD) score; those wait-listed for kidney
transplantation receive an Estimated Post-Transplant Survival (EPTS) score, and lung
transplant candidates receive a Lung Allocation Score (LAS) (Egan et al., 2006; Organ
Procurement and Transplantation Network, 2020; Veatch & Ross, 2015). More
specifically, the LAS is derived from models that predict both pre-transplant and posttransplant survival and aims to balance each patient’s predicted transplant benefit (i.e.,
difference between survival with versus without a lung transplant) against their waitlist
urgency (Egan et al., 2006; Organ Procurement and Transplantation Network, 2020;
Veatch & Ross, 2015).
Such models are particularly susceptible to selection bias. Estimates of pretransplant survival are subject to selection bias in the form of dependent censoring
because patients can be removed from the waiting list prior to one year of follow-up due
to receipt of transplant, loss to follow-up, or other clinical reasons (e.g., the inability to
withstand the transplant surgery). In each of these cases, the patients’ true one-year
pre-transplant survival is unobserved. Estimates of post-transplant survival similarly are
subject to a type of selection bias – “survivor bias” (Egleston et al., 2007; Freiman &
Small, 2014; Glymour & Greenland, 2008; Wang et al., 2017) – because they have been
derived using information only among patients who received a transplant. Thus, posttransplant survival models are applied to all wait-listed patients, but are fitted using only
transplanted patients. In particular, while statistical models used to estimate transplant
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benefit account for variation in patient characteristics, they do not account for the fact
that in order to receive a transplant, individuals must: 1) survive on the waitlist long
enough for a suitable donor organ to become available, and 2) have sufficient priority to
actually receive the organ. Since individuals who survive one year or more on the waitlist
might be inherently different from individuals who die, receive a transplant, or are
censored (e.g., lost to follow-up or removed from the waitlist for other clinical reasons,
such as being too sick to withstand the transplant surgery) prior to one year, failure to
incorporate such information in the models used to estimate transplant benefit and
waitlist urgency can lead to inaccurate predictions.
Lung transplantation represents an important example to study because it is a
highly effective treatment, but organs are scarce. Waitlist mortality is high, waitlist times
vary, and there are concerns about inequities in waitlist mortality and organ allocation
(U.S. Department of Health & Human Services, 2018). In fact, concerns about these
inequities led the Department of Health and Human Services to mandate the
development of the LAS based on medical need rather than wait time (Egan et al., 2006;
Gottlieb, 2017; U.S. Department of Health and Human Services, October 20, 1999;
United Network for Organ Sharing, 2015). Donor lungs are now allocated to recipients
based on the LAS (Egan et al., 2006; Gottlieb, 2017; U.S. Department of Health and
Human Services, October 20, 1999; United Network for Organ Sharing, 2015) which is
calculated using the predicted difference between transplant benefit and waitlist urgency,
with transplant benefit defined as one-year post-transplant survival minus one-year
waitlist survival, and waitlist urgency defined as one-year waitlist survival. Conceptually,
the LAS aims to determine the number of days of life a person would gain over the next
year if they receive transplant compared to if they do not receive transplant, and
prioritizes patients for whom this comparison is more favorable.
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We use use directed acyclic graphs (DAG) to illustrate how selection bias can
lead to inaccurate predictions for both the pre-transplant and post-transplant prediction
models. More specifically, Figure 2.1A shows the hypothesized DAG of the relationship
between patients’ covariates at the time of their hypothetical organ offer [L(0)], receipt of
transplant, and post-transplant survival prior to weighting. Whether or not a particular
individual will survive long enough to receive transplant likely depends on post-baseline
characteristics [L(t)], such as acute exacerbations of their illness and the amount of time
they have already spent on the waitlist. These variables are also likely to influence how
long the patient survives post-transplant. Before weighting, these variables are
unaccounted for. At first, failure to account for these variables might seem fine, as
Transplant is a collider on the path: Covariates informing LAS à Transplant ß L(t) à
Post-transplant survival. However, the patients who survive long enough to receive
transplant may differ from those who do not. Moreover, the estimate of post-transplant
survival used by the current LAS is inherently restricted to the former individuals. Thus, a
spurious association is induced between patients’ covariates at the time of their
hypothetical organ offer and post-transplant survival. This spurious association can lead
to biased estimates of post-transplant survival, which implies that the current
prioritization of lung transplant recipients may be inaccurate. This bias can occur even
with measured covariates, because: 1) not all measured covariates which are available
in the UNOS database are included in the LAS models (e.g., geographic differences in
transplant listing and outcomes (Thabut et al., 2012)); and 2) even if a measured
covariate is included in the LAS, the association between such a covariate and posttransplant survival can be different in the post-transplant subset than it is in the full
waitlist population.
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Figure 2.1B shows the same relationship between patients’ covariates at the time
of their hypothetical organ offer [L(0)], receipt of transplant, and post-transplant survival
after weighting. Essentially, the weighting approach we propose below capture the
information contained in L (i.e., post-baseline covariates and time on the waitlist),
thereby removing the arrows into transplant. This approach should mitigate the survivor
bias problem.
A

B

Figure 2.1. Hypothesized Directed Acyclic Graph
Hypothesized DAG depicting the relationship between patients’ covariates, receipt of transplant, and
post-transplant survival A) prior to weighting, and B) after weighting.

Although prior research has incorporated weights in the pre-transplant survival model
(Xiang & Murray, 2012), the models did not capture important geographic differences in
patient selection and survival, and no work, to our knowledge, has estimated weights to
the post-transplant survival model.
In this study, we attempt to bring principles from causal inference into the existing
prediction model framework employed by the LAS to improve organ allocation.
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Specifically, we develop a modified LAS using inverse probability weighting to improve
the accuracy of the LAS by accounting for selection bias in the pre- and post-transplant
survival models. Our work incorporates additional factors in the pre-transplant weights to
better address selection bias in the pre-transplant survival model. We also develop new
weights to address selection bias in the post-transplant survival model.

Methods
Data Source & Setup
We used publicly available pre- and post-lung transplant data from the United
Network for Organ Sharing (UNOS). Our development cohort consisted of all patients 18
years or older who were listed for single or bilateral lung transplantation in the United
States between January 1, 2010, and December 31, 2013. This date range was chosen
because it ensures that no patient experiences any person-time prior to the
implementation of the LAS (i.e., prior to May 2005) and is consistent with the
development cohort used to fit the current LAS models. Our testing cohort consisted of
patients meeting these same criteria who were listed between January 1, 2016, and
December 31, 2017 (the last complete year of available data). Patients listed during
2014 and 2015 were excluded from our analyses to ensure that 1) our development
cohort is consistent with the development cohort used to fit the current LAS; and 2) our
testing cohort does not include any patients for whom prior versions of the LAS were
used in clinical practice. To avoid concerns about positivity violations associated with the
likelihood of receiving a transplant, we removed individuals who had clinical
contraindications to receiving transplant (e.g., those with panel reactive antibodies
greater than 90%), and individuals with both restrictive lung disease (diagnosis group D)
and height less than five feet who require such small donor organs that they rarely find a
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match. In both cohorts, patients were followed from their initial listing date to their time of
transplant, death, loss to follow-up, or removal from the waitlist due to other clinical
reasons (e.g., inability to withstand the transplant surgery), whichever occurred first.
Our analysis uses daily time intervals. If individuals presented to clinic multiple
times in one day, their last record in that day was retained; conversely, if individuals did
not present to clinic in a given day, covariate information from their most recent visit was
used (i.e., last observation carried forward, LOCF). The use of LOCF is consistent with
UNOS guidelines (Organ Procurement and Transplantation Network, 2020). Any values
which remained missing (i.e., due to the absence of recent covariate values for a
particular patient) were then filled in following the UNOS value substitution policy (Organ
Procurement and Transplantation Network, 2020). This policy stipulates that if any
covariates remain missing after LOCF, then those values should be replaced with a
default value, which represents a value either in the normal range for that covariate or
which would yield the lowest LAS score for that patient. These default values are publicly
available (Organ Procurement and Transplantation Network, 2020). After data cleaning,
8379 patients provided 1,751,912 total records. These data were divided into pre- and
post-transplant subsets, with the pre-transplant subset containing daily time intervals,
and the post-transplant subset consisting of a single record per patient.

Constructing the Weights
To estimate waitlist urgency and transplant benefit, the LAS relies on two
separate outcome models. The first estimates one-year waitlist (pre-transplant) survival,
while the second estimates one-year post-transplant survival. Circumventing survivor
bias requires us to “map” the survival probabilities obtained among the post-transplant
group back to the full waitlist population. To do so, we constructed inverse probability of
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treatment weights (IPTW) and inverse probability of censoring weights (IPCW) to create
a pseudo-population which reflects the characteristics of the full waitlist population,
rather than just the subset of patients who were selected to receive transplant. This
approach accounts for differences between the post-transplant subset and the full
waitlist population that arise due to 1) measured covariates which are available in the
UNOS database, but not included in the existing LAS models; and 2) measured
covariates that are already included in the LAS, but which have a different effect on posttransplant survival in the post-transplant subset than they do in the full waitlist
population; it does not account for differences due to unmeasured covariates.
We define the following notation: 𝐴 indicates exposure (receipt of transplant); 𝐿
represents covariates; the subscript 𝑖 denotes observations pertaining to the same
subject; and the subscript 𝑘 denotes the day in which the exposure or covariates were
observed. Thus, A!" represents the observed exposure at day 𝑘 for subject 𝑖, and can
take on values a!" = 1 or a!" = 0 for transplanted or not, respectively. Similarly, L!" = 𝑙!"
represents the observed covariate values at day 𝑘 for subject 𝑖. Overbars indicate
, (!$%)" represents the vector of exposure values for
exposure or covariate history. Thus, A
subject 𝑖 up through day k − 1 (which, by design, will equal 0 up until the time subject 𝑖
receives transplant); similarly, L/!" represents the vector of covariate values for subject 𝑖
up through day k.
Weights were considered separately for the pre- and post-transplant outcome
models. The IPTW for the pre-transplant model accounts for time-varying covariate
values and variable time of transplant by patient. Stabilized IPTW (𝑠𝑤' ) were constructed
as the cumulative product of the probability of receiving transplant at each day,

17

conditional on individuals not having received transplant yet (observed through the prior
, (!$%)" )) and covariate history observed through the current day (L/!" ):
day (A
,
/
∏(
)*+ Pr [A!" = a!" |A(!$%)" = 0]
𝑠𝑤' = (
̅ ]
, (!$%)" = 0/, L/!" = l!"
∏)*+ Pr [A!" = a!" |A
The denominator of the pre-transplant IPTW weights was estimated using pooled logistic
regression, where predictors included the time-varying covariates of the published
waitlist LAS model (i.e., age, bilirubin, body mass index, cardiac index, central venous
pressure, continuous mechanical ventilation, serum creatinine, diabetes, diagnosis
group, forced vital capacity, functional status, oxygen need at rest, partial pressure of
carbon dioxide, pulmonary artery systolic pressure, six-minute walk distance), and also
blood type, gender, race, and height (consistent with (Xiang & Murray, 2012)). Additional
predictors included geography (to account for differences in survival across UNOS
regions), time (days) since waitlist registration (modeled using restricted cubic splines
with five knots; knots were chosen using Harrell’s recommended percentiles (i.e., 5,
27.5, 50, 72.5, and 95), as implemented by STATA’s mkspline function (Harrell, 2001)),
and one-month lagged versions of the covariates of the published waitlist LAS (to
capture patients’ waitlist history). The numerator of the pre-transplant IPTW weights was
also estimated using pooled logistic regression, where predictors included covariate
values at the time of waitlist registration (i.e., baseline covariates) to improve the stability
of the weights.
Stabilized IPCW (𝑠𝑐𝑤' ) were similarly constructed as the cumulative product of
the probability of being censored at each day, conditional on individuals not having been
, (!$%)" ,
censored or transplanted yet (observed through the prior day; C/(!$%)" and A
respectively) and covariate history observed through the current day (L/!" ):
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/
/ ,
/
∏(
)*+ Pr [C!" = 0|C(!$%)" = 0, A(!$%)" = 0]
𝑠𝑤_𝑐' = (
̅ ]
, (!$%)" = 0/, L/!" = l!"
∏)*+ Pr [C!" = 0|C/(!$%)" = 0/, A
These IPCW weights were obtained by fitting pooled logistic regression models with pretransplant censoring (e.g., loss to follow-up or removal from the waitlist for other clinical
reasons, such as being too sick to withstand the transplant surgery) as the outcome, and
predictors including variables in the pre-transplant LAS, these same covariates lagged
by one month, time spent on the waitlist, geography, gender, race, and height. The final,
time-varying pre-transplant weight was then calculated as the product of the stabilized
IPTW and stabilized IPCW at each time point: 𝑠𝑤𝑠𝑐𝑤' = 𝑠𝑤' ∗ 𝑠𝑐𝑤' .
Among patients who received transplant, the denominator of the IPTW is the
same as the denominator of the pre-transplant IPTW described above. The numerator,
however, includes the transplant indicator only. Covariate values at waitlist registration
were excluded from the numerator of the post-transplant IPTW because these
covariates are not present in the post-transplant outcome model (Robins et al., 2000;
Yang & Joffe, 2012). The post-transplant IPTW was then taken to be the cumulative
product of this marginally stabilized IPTW associated with the last record for each
transplanted patient in the pre-transplant data set.
The post-transplant stabilized IPCW was estimated by fitting a logistic regression
model with the post-transplant censoring variable (i.e., loss to follow-up after transplant)
as the outcome and the covariates of the published post-transplant LAS as predictors
(i.e., age, cardiac index, continuous mechanical ventilation, serum creatinine, diagnosis
group, functional status, oxygen need at rest, six-minute walk distance), along with
geography, gender, race, and time (days) spent on the waitlist (modeled using restricted
cubic splines with five knots; knots were chosen using Harrell’s recommended
percentiles (i.e., 5, 27.5, 50, 72.5, and 95), as implemented by STATA’s mkspline
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function (Harrell, 2001)). The final post-transplant weight was calculated as the product
of the stabilized IPTW and stabilized IPCW. To minimize the impact of extreme weights
on our outcome models, we progressively truncated the final pre- and post-transplant
weights following the procedure outlined in (Cole & Hernán, 2008), with weights finally
truncated at the 0.25% (99.75%) percentile. Distributions of these weights appear in
Appendix 2.1.

Fitting the outcome models
We fit a weighted Cox proportional hazards model to each patient’s baseline
record in the pre-transplant data, weighted by each patient’s daily time-varying weight to
estimate one-year pre-transplant survival accounting for dependent censoring
(Buchanan et al., 2014). This approach allows us to incorporate information from timevarying covariates and time on the waitlist captured by the IPTW and IPCW models,
while still retaining the same form of the outcome model as the current pre-transplant
LAS. It also provides predicted probabilities of one-year survival on the waitlist, which is
consistent with the definition of waitlist urgency used by the current LAS. Our weighted
Cox proportional hazards model contains all covariates included in the existing pretransplant LAS (but not follow-up time, as UNOS policy prohibits follow-up time from
being included in the outcome model). Thus, the variables in the outcome model are the
same in the modified LAS as in the existing LAS, but the coefficient estimates vary.
Similarly, we estimated one-year post-transplant survival by fitting a weighted
Cox proportional hazards model to the post-transplant subset which included the
covariates in the existing post-transplant LAS, and was weighted by each patient’s posttransplant weight (which is fixed at the time of transplant). Consistent with UNOS policy,
the post-transplant outcome model did not include time since waitlist registration. The
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estimate of one-year post-transplant survival obtained from this weighted outcome
model differs from that included in the current LAS, as the weighted outcome model
provides an estimate of survival that reflects the entire waitlist population, whereas the
current LAS estimates this quantity only among the subset of individuals who did, in fact,
receive transplant. Taken together, the weighted pre- and post-transplant outcome
models produce survival estimates that align more closely with the LAS’s conceptual
goal of comparing the number of days of life a person would gain over the next year if
they receive transplant versus if they do not receive transplant.

Assessing model performance
To assess the discrimination of the pre- and post-transplant outcome models, we
constructed time-dependent receiver operating characteristic (ROC) curves and
evaluated the area under these curves (AUC) via nearest-neighbor smoothing at one
year post-waitlist registration and one year post-transplantation, respectively (Cattaneo
et al., 2017; Heagerty et al., 2000). This approach accommodates censoring by viewing
survival time as a “time-varying binary outcome” at each possible time point, and
estimating the sensitivity and specificity of the model among all patients who are still
alive and at risk of the outcome at those time points (Cattaneo et al., 2017; Heagerty et
al., 2000). Separate statistics were computed for the development and testing cohorts.
Calibration was evaluated graphically by defining low-, medium-, and high-risk
categories based on tertiles of the linear predictor of the pre- and post-transplant
outcome models, averaging the survival functions within each of these risk categories,
and then overlaying the observed (Kaplan-Meier) and predicted survival curves for each
risk category (Royston, 2015). This approach allows us to evaluate the calibration of the
pre- and post-transplant outcome models at any time point after waiting list registration
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among all patients who are alive and at risk of the outcome at those time points
(Royston, 2015). Separate calibration plots were constructed for the development and
testing cohorts.

Comparing the modified LAS to the existing LAS
The current LAS is composed of a pre-transplant outcome model and a posttransplant outcome model, where only the pre-transplant outcome model is weighted
using a select number of covariates (Xiang & Murray, 2012). These outcome models are
used to predict one-year waitlist and one-year post-transplant survival, which are
combined into a raw score by computing one-year post-transplant survival minus two
times one-year waitlist survival (Egan et al., 2006; Organ Procurement and
Transplantation Network, 2020; United Network for Organ Sharing, 2015). This raw
score is normalized so that it ranges from 0 to 100, with higher values indicating greater
priority for transplantation (Egan et al., 2006; Organ Procurement and Transplantation
Network, 2020; United Network for Organ Sharing, 2015). We construct modified preand post-transplant outcome models by applying weights to both models, as described
above. We applied the weighted pre- and post-transplant outcome models to the testing
cohort to estimate a modified LAS score for each patient considering all possible offer
dates in 2016 and 2017. At each offer date, we subset the data to include only patients
who were alive, registered on the waitlist, and not yet transplanted at that date. Then, we
computed modified waitlist urgency and modified post-transplant survival measures
following UNOS guidelines (Organ Procurement and Transplantation Network, 2020;
United Network for Organ Sharing, 2015). We computed daily, person-specific survival
estimates for the first year spent on the waitlist and the first year post-transplant using
the baseline hazard, weighted model coefficients, and each individual’s covariate values.
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Each patients’ resulting waitlist and post-transplant survival probabilities were summed
to obtain the modified waitlist urgency (𝑚𝑊𝐿' ) and modified post-transplant survival
(𝑚𝑃𝑇' ) measures:
012

𝑚𝑊𝑎𝑖𝑡' = F 𝑆,-'.,()$%)' ∗ 1 𝑑𝑎𝑦
)*%
012

𝑚𝑃𝑇' = F 𝑆34,()$%)' ∗ 1 𝑑𝑎𝑦
)*%

where 𝑆,-'.,()$%)' and 𝑆45,()$%)' respectively represent the pre-transplant (waitlist) and
post-transplant survival probabilities for subject 𝑖 at day 𝑘 − 1. The modified raw score
was then computed as:
𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑅𝑎𝑤 𝑆𝑐𝑜𝑟𝑒 = 𝑚𝑃𝑇' − 2 ∗ 𝑚𝑊𝑎𝑖𝑡'

Taking into account the maximum and minimum pre- and post-transplant survival, the
modified raw score was normalized via the following equation, consistent with the
existing LAS:
𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐿𝐴𝑆 =

100 ∗ [(𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑅𝑎𝑤 𝑆𝑐𝑜𝑟𝑒' ) + 730]
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Existing LAS scores were estimated for each patient by applying the published
pre- and post-transplant LAS models to the testing cohort following the same procedure
as above (Organ Procurement and Transplantation Network, 2020; United Network for
Organ Sharing, 2015) with coefficients from the existing LAS. Last, we constructed two
sets of rankings for eligible patients at each offer date: rankings based on their modified
LAS scores and rankings for the same patients based on their existing LAS scores.
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To assess the difference between the modified and existing LAS models, we
constructed Bland-Altman plots of 1) the modified LAS score versus the existing LAS
score; and 2) the modified patient rank versus the existing patient rank (Bland & Altman,
1986). We also created a scatter plot of the difference in estimated post-transplant
survival versus the difference in pre-transplant survival obtained under the modified and
existing LAS models to examine which of these factors drive changes in patient
prioritization.
Analyses were conducted using Stata (StataCorp LLC, College Station, TX) and
R (R Foundation for Statistical Computing, Vienna, Austria).

Results
Table 2.1 displays demographic and clinical characteristics of the complete
waiting list population at the time of waitlist registration in the development and testing
cohorts. Table 2.2 displays similar information at the time of transplantation for the
subset of patients in each cohort who received transplant.

Table 2.1. Demographic and clinical characteristics of the complete waiting list population in the
development and testing cohorts
Covariates are measured at the time of waitlist registration in both cohorts.
Total number of patients (N)
Waiting time (days), median (IQR)
Death on waitlist within 1 year of waitlist registration
All deaths on waitlist
Removal from waitlist due to transplant
REGION
1
2
3
4
5
6
7
8
9
10
11
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Development Cohort
8379
73.0 (19.0, 237.0)
56 (0.7%)
751 (9.5%)
7157 (85.4%)

Testing Cohort
5354
57.0 (16.0, 154.0)
25 (0.5%)
288 (5.7%)
4154 (77.6%)

251 (3.0%)
1264 (15.1%)
951 (11.3%)
1216 (14.5%)
1203 (14.4%)
208 (2.5%)
607 (7.2%)
502 (6.0%)
285 (3.4%)
999 (11.9%)
893 (10.7%)

185 (3.5%)
953 (17.8%)
522 (9.7%)
636 (11.9%)
878 (16.4%)
110 (2.1%)
438 (8.2%)
312 (5.8%)
180 (3.4%)
684 (12.8%)
456 (8.5%)

GENDER
F
M
RACE/ETHNICITY
White
Black
Hispanic
Asian
Other
DIAGNOSIS
A (Obstructive Disease)
B (Pulmonary Hypertension)
C (Cystic Fibrosis)
D (Pulmonary Fibrosis)
BLOOD TYPE
A
AB
B
O
Age (years), median (IQR)
Bilirubin (mg/dL), median (IQR)
BMI (kg/m3), median (IQR)
Height (feet), median (IQR)
Cardiac index <2 L/min/m2
Central venous pressure (mmHg), median (IQR)
Continuous mechanical ventilation
Creatinine (serum) (mg/dL), median (IQR)
Diabetes
Forced vital capacity % predicted, median (IQR)
Functional status (none)
Oxygen need at rest (L/min), median (IQR)
pCO2, median (IQR)
Pulmonary artery systolic pressure (mmHg), median (IQR)
Six-minute walk distance (feet), median (IQR)

3520 (42.0%)
4859 (58.0%)

2263 (42.3%)
3091 (57.7%)

6966 (83.1%)
738 (8.8%)
494 (5.9%)
131 (1.6%)
50 (0.6%)

4224 (78.9%)
552 (10.3%)
411 (7.7%)
124 (2.3%)
43 (0.8%)

2423 (28.9%)
398 (4.7%)
975 (11.6%)
4583 (54.7%)

1444 (27.0%)
299 (5.6%)
538 (10.0%)
3073 (57.4%)

3297 (39.3%)
307 (3.7%)
916 (10.9%)
3859 (46.1%)
59.0 (49.0, 65.0)
0.7 (0.7, 0.7)
25.5 (21.6, 28.9)
5.6 (5.3, 5.8)
2096 (25.0%)
5.0 (5.0, 8.0)
301 (3.6%)
0.8 (0.7, 1.0)
1892 (22.6%)
48.0 (38.0, 61.0)
1027 (12.3%)
3.0 (2.0, 6.0)
42.0 (40.0, 49.0)
37.0 (30.0, 47.0)
870.0 (550.0, 1176.0)

2100 (39.2%)
195 (3.6%)
607 (11.3%)
2452 (45.8%)
60.0 (52.0, 66.0)
0.7 (0.7, 0.7)
26.0 (22.0, 29.2)
5.6 (5.3, 5.8)
896 (16.7%)
5.0 (5.0, 8.0)
217 (4.1%)
0.8 (0.7, 1.0)
1074 (20.1%)
48.0 (38.0, 62.0)
604 (11.3%)
4.0 (2.0, 6.0)
43.0 (40.0, 50.0)
38.0 (31.0, 48.0)
880.5 (580.0, 1142.0)

Table 2.2. Demographic and clinical characteristics of the subset of individuals who received
transplant in the development and testing cohorts
Covariates are measured at the time of transplantation in both cohorts.
Total number of patients (N)
Follow-up time post-transplant (days), median (IQR)
Death within 1 year of transplant
All deaths post-transplant
REGION
1
2
3
4
5
6
7
8
9
10
11
GENDER
F
M
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Development Cohort
7074
1439.0 (721.0, 1834.0)
935 (13.2%)
3063 (43.7%)

Testing Cohort
4154
199.0 (68.0, 365.0)
346 (8.3%)
420 (10.9%)

201 (2.8%)
1068 (15.1%)
784 (11.1%)
1030 (14.6%)
1031 (14.6%)
174 (2.5%)
503 (7.1%)
432 (6.1%)
241 (3.4%)
794 (11.2%)
816 (11.5%)

160 (3.9%)
680 (16.4%)
405 (9.7%)
534 (12.9%)
675 (16.2%)
67 (1.6%)
334 (8.0%)
251 (6.0%)
126 (3.0%)
528 (12.7%)
394 (9.5%)

2780 (39.3%)
4294 (60.7%)

1594 (38.4%)
2560 (61.6%)

RACE/ETHNICITY
White
Black
Hispanic
Asian
Other
DIAGNOSIS
A (Obstructive Disease)
B (Pulmonary Hypertension)
C (Cystic Fibrosis)
D (Pulmonary Fibrosis)
BLOOD TYPE
A
AB
B
O
Age (years), median (IQR)
Bilirubin (mg/dL), median (IQR)
BMI (kg/m3), median (IQR)
Height (feet), median (IQR)
Cardiac index <2 L/min/m2
Central venous pressure (mmHg), median (IQR)
Continuous mechanical ventilation
Creatinine (serum) (mg/dL), median (IQR)
Diabetes
Forced vital capacity % predicted, median (IQR)
Functional status (none)
Oxygen need at rest (L/min), median (IQR)
pCO2, median (IQR)
Pulmonary artery systolic pressure (mmHg), median (IQR)
Six-minute walk distance (feet), median (IQR)

5938 (83.9%)
581 (8.2%)
405 (5.7%)
107 (1.5%)
43 (0.6%)

3339 (80.4%)
397 (9.6%)
299 (7.2%)
93 (2.2%)
26 (0.6%)

2792 (39.5%)
265 (3.7%)
764 (10.8%)
3253 (46.0%)

1038 (25.0%)
182 (4.4%)
436 (10.5%)
2498 (60.1%)

2821 (39.6%)
266 (3.7%)
772 (10.8%)
3272 (45.9%)
60.0 (50.0, 65.0)
0.7 (0.7, 0.7)
25.4 (21.6, 28.8)
5.6 (5.3, 5.8)
1406 (19.9%)
5.0 (5.0, 8.0)
457 (6.5%)
0.8 (0.7, 1.0)
1725 (24.4%)
45.0 (35.0, 57.0)
414 (5.9%)
4.0 (3.0, 6.0)
45.0 (40.0, 53.0)
38.0 (32.0, 48.0)
774.0 (403.0, 1068.0)

1702 (41.0%)
157 (3.8%)
474 (11.4%)
1821 (43.8%)
61.0 (52.0, 66.0)
0.7 (0.7, 0.7)
25.9 (22.1, 29.0)
5.6 (5.3, 5.8)
596 (14.3%)
5.0 (5.0, 8.0)
320 (7.7%)
0.8 (0.7, 1.0)
971 (23.4%)
45.0 (36.0, 58.0)
209 (5.0%)
4.0 (2.5, 8.0)
45.0 (40.0, 53.0)
38.0 (31.0, 49.0)
800.0 (445.0, 1059.0)

Overall, the full waiting list population is comparable in the development and testing
cohorts. The subset of transplanted individuals are also comparable across cohorts.
However, the amount of pre- and post-transplant follow-up time and the number of
deaths (outcome events) are noticeably smaller in the testing cohort compared to the
development cohort. This discrepancy is due to the fact that the UNOS data to which we
have access was administratively censored in 2018. Thus, any pre- or post-transplant
deaths that occurred beyond this date are not counted. As more follow-up time accrues,
the number of pre- and post-transplant deaths in the testing cohort should increase,
which will lead to increased precision in the observed Kaplan-Meier survival estimates
discussed below.
Table 2.3 displays the parameter estimates obtained for the modified (weighted)
pre- and post-transplant outcome models.
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Table 2.3. Parameter estimates obtained from the modified (weighted) pre- and post-transplant
outcome models

Table 2.3A) Parameter estimates obtained for the modified pre-transplant outcome model

Coefficient
Estimate
-0.0024318
0
0
0.0104932
0.4723494
-0.0503087
1.22271
0.0864787
0.3591762
REF
0.665212
0.2546667
0.8609124
0.0682059
0.0379326
0.0520477
0.0301022
0.1595511
0
0.1009163
0.0040516
-0.0130285

Covariate
Age at offer (years)
Bilirubin (mg/dL)
Bilirubin increase ≥50%
Body mass index (BMI) (kg/m3)
Cardiac index (L/min/m2)
Central venous pressure (CVP) (mmHg)
Continuous mechanical ventilation
Creatinine (serum) (mg/dL)
Diabetes
Diagnosis Group A
Diagnosis Group B
Diagnosis Group C
Diagnosis Group D
Forced vital capacity (FVC) % predicted
Functional status (none)
Oxygen need at rest (L/min)
Oxygen-by-diagnosis interaction
pCO2
pCO2 increase ≥15%
Pulmonary artery (PA) systolic pressure (mmHg)
PA-by-diagnosis interaction
Six-minute walk distance (feet)

95% Confidence Interval
-0.0113106, 0.0064469
(omitted)
(omitted)
-0.0058752, 0.0268615
0.2710321, 0.6736667
-0.1253766, 0.0247593
0.6709733, 1.774447
0.0193925, 0.1535648
0.137798, 0.5805544
0.0004605, 1.329963
-0.2330827, 0.7424161
0.3824339, 1.339391
-0.0151386, 0.1515504
-0.32105, 0.3969151
0.024774, 0.0793213
-0.0152716, 0.0754759
0.0794078, 0.2396944
(omitted)
0.0482246, 0.153608
-0.0967816, 0.1048847
-0.0300434, 0.0039865

Table 2.3B) Parameter estimates obtained for the modified post-transplant outcome model

Coefficient
Estimate
0.0310272
0.1035634
0.5672613
0.2231819
0
REF
0.3578133
0.16691
0.0524997
-0.2999765
0.0166301
-0.0094877
-0.0000709

Covariate
Age at transplant (years)
Cardiac index (L/min/m2)
Continuous mechanical ventilation
Creatinine (serum) (mg/dL)
Creatinine increase ≥150%
Diagnosis Group A
Diagnosis Group B
Diagnosis Group C
Diagnosis Group D
Functional status (none)
Oxygen need at rest (L/min)
Oxygen-by-diagnosis interaction
Six-minute walk distance (feet)
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95% Confidence Interval
0.0212575, 0.0407969
-0.0367848, 0.2439117
0.1808594, 0.9536632
0.0890585, 0.3573053
(omitted)
0.0197239, 0.6959027
-0.123965, 0.4577851
-0.1283522, 0.2333516
-0.5940731, -.00588
0.0014614, 0.0317989
-0.039502, 0.0205267
-0.0002148, 0.0000729

These parameter estimates were used in conjunction with the baseline survival
probabilities shown in Appendix 2.2 to construct modified LAS scores for patients in our
testing cohort.
Table 2.4 displays the time-dependent AUC (Cattaneo et al., 2017; Heagerty et
al., 2000) evaluated at one year post-waitlist registration and one year post-transplant for
the modified and existing LAS models in the development and testing cohorts. In all
cases, the AUC of the modified model is higher than that of the existing LAS, indicating
that the modified model has better discrimination. However, the extent of improvement is
larger in the pre-transplant population than in the post-transplant population.
Table 2.4. Time-dependent AUC for the modified and existing LAS
Time-dependent AUC estimated via nearest-neighbor smoothing at one year post-waitlist
registration and one year post-transplant for the modified and existing LAS models. 95% confidence
intervals were computed via the bootstrap percentile method; p-values were estimated using the
normal approximation and standard deviation obtained from the bootstrap replicates. 1000 bootstrap
replicates were used.

Cohort*
Pre-tx
Development
Post-tx
Pre-tx
Testing
Post-tx

Modified LAS

Existing LAS

Difference

0.732
(0.690, 0.760)
0.605
(0.580, 0.629)
0.750
(0.686, 0.792)
0.570
(0.536, 0.606)

0.660
(0.619, 0.697)
0.560
(0.531, 0.585)
0.693
(0.631, 0.738)
0.540
(0.507, 0.576)

0.071
(0.030, 0.106)
0.045
(0.026, 0.065)
0.057
(-0.004, 0.122)
0.030
(0.003, 0.058)

p-value of
difference
<0.001
<0.001
0.083
0.030

* tx = transplant

Figure 2.2 depicts the time-dependent calibration of the modified pre- and posttransplant outcome models and existing pre- and post-transplant LAS models in the
development cohort for the first two years post-listing and post-transplant. The predicted
survival curves from the modified pre-transplant outcome model agree more closely with
the observed survival curves for all three risk categories when compared with the
existing LAS model. Conversely, predictions from the existing pre-transplant LAS model
are noticeably different from the observed survival curves (Figure 2.2B).
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Figure 2.2. Observed vs. Predicted Survival in Development Cohort
Time-dependent calibration of A) the modified pre-transplant outcome model, B) the existing pretransplant LAS model, C) the modified post-transplant outcome model, and D) the existing posttransplant LAS model, in the development cohort. Smooth, solid lines represent predicted survival
probabilities; points with vertical error bars represent observed Kaplan-Meier estimates with their
corresponding 95% confidence intervals. Estimates were plotted every 30 days to ease plot
readability. Three risk groups are shown: low-risk/best survival (darkest lines), mediumrisk/intermediate survival (medium-shaded lines), and high-risk/worst survival (lightest lines). A
vertical, dashed, red line is placed at one year post-waitlist registration for reference.

This discrepancy is most prominent during the first year post-waitlist registration, but
continues beyond this time point for all three risk groups (Figure 2.3). In contrast,
predicted survival estimates from the modified post-transplant outcome model (Figure
2.2C) and the existing post-transplant LAS model (Figure 2.2D) closely match the
observed survival curves. This observation is consistent with the AUC results in Table
2.4, and suggests that the extent of improvement in calibration is more noticeable for the
pre-transplant model than the post-transplant model.
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Figure 2.3. Long Term Observed vs. Predicted Survival in Development Cohort
Time-dependent calibration of A) the modified pre-transplant outcome model, B) the existing pretransplant LAS model, C) the modified post-transplant outcome model, and D) the existing posttransplant LAS model, in the development cohort. Smooth, solid lines represent predicted survival
probabilities; points with vertical error bars represent observed Kaplan-Meier estimates with their
corresponding 95% confidence intervals. Estimates were plotted every 30 days to ease plot
readability. Three risk groups are shown: low-risk/best survival (darkest lines), mediumrisk/intermediate survival (medium-shaded lines), and high-risk/worst survival (lightest lines). A
vertical, dashed, red line is placed at one year post-waitlist registration for reference.

Similar results were obtained in the testing cohort (Figure 2.4). In the testing
cohort, the predicted survival estimates from the modified pre-transplant outcome model
were consistent with the observed survival curves over time, regardless of risk group
(Figure 2.4A). Predictions obtained from the existing pre-transplant LAS model,
however, did not align as well with observed survival (Figure 2.4B). The modified and
existing post-transplant models exhibit similar calibration in the testing cohort (Figures
2.4C and 2.4D, respectively). The calibration of both models is quite good in the first
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year post-transplant but deteriorates considerably beyond one year for all three risk
groups.
A

B

C

D

Figure 2.4. Observed vs. Predicted Survival in Testing Cohort
Time-dependent calibration of A) the modified pre-transplant outcome model, B) the existing pretransplant LAS model, C) the modified post-transplant outcome model, and D) the existing posttransplant LAS model, in the testing cohort. Smooth, solid lines represent predicted survival
probabilities; points with vertical error bars represent observed Kaplan-Meier estimates with their
corresponding 95% confidence intervals. Estimates were plotted every 30 days to ease plot
readability. Three risk groups are shown: low-risk/best survival (darkest lines), mediumrisk/intermediate survival (medium-shaded lines), and high-risk/worst survival (lightest lines). A
vertical, dashed, red line is placed at one year post-waitlist registration for reference.

Figure 2.5 depicts Bland-Altman plots of A) the modified versus existing LAS
score, and B) the modified versus existing patient rank, for 712 different organ offer
dates in the testing cohort. Patients at the extremes tend to receive similar scores under
the two models, while patients with intermediate scores tend to experience more
changes under the modified LAS. Specifically, a distinct cluster of patients appears more
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than 2 standard deviations below the mean; for these patients, the modified LAS predicts
a lower score than the existing LAS does. The Bland-Altman plot of changes in rank
(Figure 2.5B) exhibits a somewhat different pattern than that in Figure 2.5A due to
constraints of ranks (i.e., individuals who receive a more favorable rank are necessarily
balanced by those who receive a less favorable one).
A

B

Figure 2.5. Bland-Altman plots
A) Difference between the modified and existing LAS scores versus the mean of the two scores, and
B) difference between the modified and existing patient ranks versus the mean of the two ranks,
from 712 different organ offer dates in the testing cohort. Horizontal, dashed lines are placed at ±𝟐
standard deviations of the mean.

Figure 2.6 illustrates how differences in estimated pre- and post-transplant
survival under the modified and existing LAS models influence patients’ LAS scores
(Figure 2.6A) and prioritization (Figure 2.6B) for 712 organ offer dates in the testing
cohort. Consistent with Figure 2.5A, the majority of patients in Figure 2.6A are shaded
white or blue, indicating that these patients would receive the same or lower score under
the modified model compared with the existing LAS. This lower score does not always
translate into a lower (worse) priority, because the rank of a particular patient on a
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particular organ offer date depends on the ranks of all other eligible patients on the
waitlist at that date. Consequently, the distribution of shading in Figure 2.6B differs from
that in Figure 2.6A. In both figures, however, differences in pre-transplant survival
explain a greater proportion of the variability in the outcome (i.e., change in LAS score or
change in priority) compared to differences in post-transplant survival.
A

B

Figure 2.6. Scatter plots of the difference in post-transplant survival versus the difference in waitlist
survival obtained under the modified and existing LAS in the testing cohort
Differences are computed for 712 organ offer dates in the testing cohort. Points represent patients,
and are shaded based on the magnitude of change in A) score, with red representing increases in
score and blue representing decreases in score; or B) rank, with red representing higher (better)
priority and blue representing lower (worse) priority.

Discussion
We developed a weighted estimation strategy to account for selection bias in the
pre- and post-transplant models used to calculate LAS scores in prioritizing patients for
lung transplant. To our knowledge, we are the first to incorporate weighting into the
fitting of post-transplant models to account for survivor bias and other forms of selection
into the post-transplant population. We also improve upon weighted fitting of pretransplant models by incorporating additional variables in our weight models to better
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account for dependent censoring – most notably, geography. Since these variables are
only included in the weight models (not the outcome models), they would only influence
the performance of the outcome model if they are associated both with survival and with
patients’ selection for transplantation. The fact that discrimination and calibration
improve under the modified pre- and post-transplant outcome models compared to the
existing LAS models suggests that regional differences in patient selection may be
important to consider when estimating pre- and post-transplant survival. That said, the
extent of improvement is larger in the pre-transplant population (i.e., the full waiting list
population) than in the post-transplant subset. There are two potential explanations for
this observation: first, we have considerably more follow-up time in the pre-transplant
population than in the post-transplant population; and second, selection bias appeared
to have a larger impact on the estimate of waiting list urgency than on the estimate of
post-transplant survival.
We postulated that the current LAS underestimates predicted transplant benefit
due to survivor bias because it only predicts this quantity among people who were
indeed selected to receive transplant, who tend to be older and sicker. Our results (e.g.,
Figures 2.6A and 2.6B) are consistent with this idea because they suggest that patients’
estimated post-transplant survival under the modified LAS would be the same or greater
than their estimated post-transplant survival under the existing LAS. Because the
estimate of pre-transplant survival also tends to be longer under the modified LAS
compared to the existing LAS, a sizable number of patients with intermediate scores
under the current LAS would receive lower scores (lower priority) under the modified
LAS.
Our study has several strengths. We demonstrate how inverse probability
weighting can account for survivor bias in real-world lung transplant data. These weights
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account for the probability of receiving transplant as well as the probability of censoring.
By including additional variables in our weighting, such as geography and prior (i.e.,
lagged) clinical covariates, we account for regional variability in pre- and post-transplant
survival and are able to capture patients’ waitlist history and clinical trajectory more fully,
while maintaining consistency between our modified outcome model and the existing
LAS. This approach ensures a fair comparison between the modified and existing
models in both the development and testing cohorts. Although our primary endpoints
were one-year pre- and post-transplant survival, the results using greater extent of
follow-up time demonstrate how these models perform over longer time frames. Such an
evaluation can help inform future revisions of the LAS, and is especially relevant as the
lung transplant community considers what role longer-term survival should play in lung
allocation (Kasiske et al., 2020; Maxwell et al., 2014; U.S. Department of Health &
Human Services). Finally, while our analysis focuses on lung allocation specifically, our
approach can be applied to any organ allocation system that relies on estimates of posttransplant survival to prioritize patients (e.g., the United States’ EPTS score for kidney
allocation (Egan et al., 2006; Organ Procurement and Transplantation Network, 2020;
Veatch & Ross, 2015), Germany’s Lung Allocation Score (Gottlieb, 2017; Gottlieb et al.,
2014), and the United Kingdom’s Liver Transplant Benefit Score (NHS Blood and
Transplant)).
Our study is not without limitations. First, insufficient information is available to
distinguish between patients who were newly listed and those who were re-activated
after temporary waitlist removal. Thus, the first record associated with each identification
number was taken to be the initial registration date, follow-up time was counted from that
date forward, and individuals who were subsequently lost to follow-up were censored at
that time. Second, we exclude individuals on the waitlist who are highly unlikely to
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receive transplant, due to certain patient characteristics that prevent them from finding a
suitable donor organ match (e.g., high sensitization or small stature). Although this
analytic decision ensures that the remaining individuals on the waitlist have at least
some probability of receiving transplant, it also implies that we can only generalize our
findings to individuals on the waitlist who do not have these clinical contraindications.
Third, we cannot account for ascertainment bias/informed presence bias (i.e., we cannot
account for the fact that presence in the UNOS database is not random, but rather
indicates that the patient was ill enough to visit the hospital, undergo evaluation for
transplant, and be registered on the waitlist). Fourth, transplant organ allocation is a
highly selective process, and selection bias can occur at various stages throughout this
process (e.g., decision to register a patient on the waitlist, decision to remove a
waitlisted patient, decision to transplant). In this particular paper, we restrict our focus to
selection bias that arises due to the fact that some individuals die or are otherwise
censored prior to receiving transplant, and present a quantitative approach to mitigating
this bias in the LAS. Although beyond the scope of this study, additional research –
including qualitative work – is necessary to understand how to balance all the factors
that go into making transplant decisions.
Our approach to addressing selection bias is intuitive and straightforward to
implement, and demonstrates how principles from causal inference can be incorporated
into existing prediction model frameworks to improve organ allocation. Additionally, it can
be applied to any organ allocation system that relies on estimates of pre- and posttransplant survival to prioritize patients, including those used for different organs and in
other countries. We anticipate that this work can inform future revisions of the LAS and
other prediction models in organ transplantation to improve prediction and ensure fair
and equitable organ allocation.
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CHAPTER 3. CLINICAL IMPACT OF A MODIFIED LUNG ALLOCATION SCORE THAT
MITIGATES SELECTION BIAS

This chapter is under review. The suggested citation is:
Schnellinger EM, Cantu E, Schaubel DE, Kimmel SE, Stephens-Shields AJ. Clinical Impact of a
Modified Lung Allocation Score that Mitigates Selection Bias (under review).
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Abstract
Background. The Lung Allocation Score (LAS) is used in the U.S. to prioritize lung
transplant candidates. Selection bias, induced by dependent censoring of waitlisted
candidates and prediction of post-transplant survival among surviving, transplanted
patients only, is only partially addressed by the LAS. Recently, a modified LAS (mLAS)
was designed to mitigate such selection biases. Here, we estimate the clinical impact of
replacing the LAS with the mLAS.
Methods. We considered lung transplant candidates waitlisted during 2016-2017.
Modified and existing LAS scores were computed for each registrant at each observed
organ offer date; individuals were ranked accordingly. Patient characteristics associated
with better priority under the mLAS were investigated via logistic regression and
generalized linear mixed models. We also determined whether differences in rank were
explained more by changes in predicted pre- or post-transplant survival. Simulations
examined how one-year waitlist, post-transplant, and overall survival might change
under the mLAS.
Results. Diagnosis group, six-minute walk distance, continuous mechanical ventilation,
functional status, and age demonstrated the highest impact on differential allocation.
Changes in predicted pre-transplant survival explained a greater proportion of variability
in differences in rank than changes in predicted post-transplant survival, suggesting that
selection bias has a larger impact on the estimate of waitlist urgency than on the
estimate of post-transplant survival. Simulations suggest that for every 1000 waitlisted
individuals, 12.8 (interquartile range, IQR: 5.2-24.3) fewer waitlist deaths per year would
occur under the mLAS, without compromising post-transplant and overall survival.
Conclusions. Implementing a modified LAS that mitigates selection bias into clinical
practice can lead to important differences in allocation and possibly modest
improvement in waitlist survival.
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Background
The U.S. lung allocation system prioritizes lung transplant candidates based on
the Lung Allocation Score (LAS) (Organ Procurement and Transplantation Network,
2020). The LAS aims to predict how long a patient would survive with versus without a
transplant, and is composed of two prediction models: one to predict pre-transplant
survival and one to predict post-transplant survival (Egan et al., 2006). Patients’
transplant benefit is estimated as the difference between predicted post- and pretransplant survival, while their waitlist urgency is taken to be predicted pre-transplant
survival (Egan et al., 2006; United Network for Organ Sharing, 2015). The LAS is
computed as the difference between transplant benefit and waitlist urgency
(equivalently, post-transplant survival minus two times pre-transplant survival), and is
normalized so that it ranges between 0 and 100, with higher scores indicating greater
priority for transplant (United Network for Organ Sharing, 2015).
Although LAS scores are calculated using each patient’s most recent
demographic and clinical variables, the models used to predict pre- and post-transplant
survival underlying the LAS do not fully account for selection bias. Such bias arises due
to dependent censoring (individuals are removed from the waitlist once they receive
transplant) and survivor bias (individuals must survive long enough for a suitable donor
organ to become available) (Schnellinger et al., 2021). In Chapter 2, we developed a
modified LAS using inverse probability of treatment weighting (IPTW) and inverse
probability of censoring weighting (IPCW) in order to mitigate selection bias. We then
demonstrated improved discrimination and calibration for the modified LAS compared to
the existing LAS. We also showed that the modified LAS would affect patient rankings
considerably.
In this chapter, we evaluate the impact of implementing this modified LAS in
clinical practice. More specifically, we use observed data to investigate the demographic
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and clinical characteristics of individuals who would have received better priority under
the modified LAS compared to the existing one. We also conduct a simulation study to
estimate how waitlist, post-transplant, and overall survival might change under the
modified LAS. Understanding the clinical impact of the modified LAS is especially
relevant now, as the transplant community is currently developing and implementing a
new organ allocation framework, the continuous distribution model, which aims to
increase the flexibility of the scoring algorithm so that organs are allocated to patients
more equitably. Note that the sources of bias we outline above would still be in play
under this continuous distribution model unless they are recognized and addressed
(Kasiske et al., 2020; Snyder et al., 2018; U.S. Department of Health & Human
Services).

Methods
This study utilizes pre- and post-lung transplant data from the United Network for
Organ Sharing (UNOS). Our cohort consisted of all patients 18 years or older who were
listed for single or bi-lateral lung transplantation in the United States between January 1,
2016, and December 31, 2017. This cohort is consistent with the testing cohort used in
Chapter 2 and our earlier paper (Schnellinger et al., 2021).
We applied the modified and existing LAS models to our cohort to estimate both
a modified LAS score and an existing LAS score for each patient at each possible offer
date, as in Chapter 2 and our previous paper (Schnellinger et al., 2021). At each offer
date, eligible patients were ranked twice: first using their modified LAS scores, and
second using their existing LAS scores. Patients were then grouped into two categories
(better versus same or worse priority) based on how their rank would change under the
modified LAS compared to the existing LAS. We were unable to analyze the better
priority, same priority, and worse priority categories separately because the sample size
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among individuals who received the same rank under the two LAS models was too
small. Moreover, dropping individuals who received the same rank from the analyses
entirely would alter the interpretation of the resulting probabilities (i.e., they would be
interpreted as conditional rather than marginal probabilities). Thus, we combined
individuals who received the same rank together with individuals who received worse
priority. Although we could have instead grouped individuals who received the same
rank with those who received better priority, we felt that keeping the better priority
individuals separate would be more meaningful to patients and clinicians, as this
category then represents individuals whose chances of receiving transplant would
increase under the modified LAS.
To examine the demographic and clinical characteristics of patients who receive
better priority under the modified LAS relative to the existing LAS, univariable and
multivariable logistic regression models were fit. The outcome variable for these models
was categorical change in rank (better priority versus no change or worse priority), and
predictors included patients’ diagnosis group, age, gender, race/ethnicity, primary
payment source, education level, employment status, UNOS geographic region, body
mass index (BMI), blood type, HLA mismatch, prior transplant, prior cardiac surgery,
smoking status, diabetes, functional status, cardiac index, mechanical ventilation, sixminute walk distance, creatinine, and oxygen need at rest. Covariates were only
included in the multivariable model if they were statistically significant at the 𝛼 = 0.05
level in the univariable models. Based on the multivariable model, bar charts of the
predicted probability of receiving better priority under the modified LAS compared to the
existing LAS were constructed for each covariate individually.
To evaluate the extent to which changes in prioritization are driven by changes in
predicted pre- or post-transplant survival between the modified and existing LAS, we
subset the data into two groups: one with only worse priority individuals, and another
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with only better priority individuals. Generalized linear mixed models (GLMM) were fit to
each subset using the continuous differences in ranks for each patient under the
modified and existing LAS, and the difference in predicted pre-transplant survival and
difference in predicted post-transplant survival as predictors. Generalized r2 values were
obtained for each GLMM model via the r2glmm package (Jaeger, 2017). We also
conducted these analyses stratified by the demographic and clinical characteristics that
were deemed to have a significant impact on prioritization changes based on the logistic
regression models.
Finally, we undertook a statistical simulation – adapted from (Vock et al., 2013) –
to investigate how the modified LAS would impact observed waitlist and post-transplant
survival if it were implemented in clinical practice. Specifically, we:
1. Selected a random set of 364 offer dates from the observed offer dates in the
testing cohort.
2. Assigned the number of organ offers per day by drawing from a Poisson
distribution with a mean of 6, which equals the observed mean number of
offers per day in the testing cohort.
3. Simulate characteristics of the hypothetical donor organs – e.g., donor region
and donor blood type – by randomly sampling from the observed distribution
of donor organ characteristics in the testing cohort.
4. Simulate waitlist survival (i.e., transplant-free survival) for all individuals by
drawing from an exponential distribution with rate parameter depending on
their predicted probability of waitlist death in the next month associated with
their baseline (i.e., waitlist registration) record. Further details on how we
obtained these predicted probabilities appear below.
5. At each offer date, compute a modified LAS score and an existing LAS score
for each patient alive and eligible to receive transplant on that date. If an
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individual’s simulated death date exceeds their last observed visit date,
linearly interpolate their LAS such that it increases from their final observed
value to halfway between that value and 100 (as per (Vock et al., 2013)). This
approach simulates how patients tend to become sicker the longer they
remain on the waitlist.
6. At each offer date, conduct two separate allocations, one based on patients’
existing LAS scores, and a second based on their modified LAS scores. In
each allocation, we subset the set of eligible patients to include only those
who match the characteristics of the hypothetical donor organ. Then, rank the
patients in this subset by their modified and existing LAS scores, and allocate
the hypothetical organ to the highest ranking person under each scoring
system. Offers were first extended to recipients in the same region and same
blood type as the donor lung. If no one met those criteria, we successively
relaxed the matching criteria (same region, compatible blood type; nearby
region, same blood type; nearby region, compatible blood type; any region,
same blood type; any region, compatible blood type) until a match could be
made.
7. If a patient was selected to receive the hypothetical organ offer in step (6),
simulate their post-transplant survival by drawing from an exponential
distribution with rate parameter depending on their predicted probability of
one-year post-transplant death associated with the time at which they receive
the hypothetical transplant. Further details on how we obtained these
predicted probabilities appear below.
8. Repeat steps (6) and (7) until all hypothetical donor organs are allocated.
9. Generate patients’ final pre- or post-transplant outcome status, as
appropriate. Specifically:
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a. if patients do not receive a hypothetical transplant in the simulation,
generate their final waitlist outcome status by drawing from a Bernoulli
distribution with a probability equal to their predicted probability of
waitlist death in the next month given that they survived through the
time point associated with their final waitlist record; set their posttransplant outcome status to missing.
b. if patients receive a hypothetical transplant in the simulation, censor
their final waitlist outcome at the time they receive the hypothetical
transplant; generate their final post-transplant outcome status by
drawing from a Bernoulli distribution with a probability equal to their
predicted probability of one-year post-transplant death that
corresponds with the time they received the hypothetical transplant.
10. At the end of each iteration, compute Kaplan-Meier estimates of one-year
waitlist, one-year post-transplant, and one-year overall survival among the
entire simulated population. Also compute the proportion of patients who
receive hypothetical transplant under both the existing LAS and the modified
LAS (concordant set).
11. Among individuals who receive hypothetical transplant under one LAS but not
the other (discordant set), compute the same Kaplan-Meier estimates as in
(10). Also calculate means and proportions (as appropriate) of time-invariant
demographic and clinical characteristics.

The predicted probabilities used to generate transplant-free survival in step (4) were
obtained by fitting a discrete-time pooled logistic regression model with waitlist mortality
as the outcome and the covariates of the existing waitlist LAS model (i.e., age, bilirubin,
body mass index, cardiac index, central venous pressure, continuous mechanical
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ventilation, serum creatinine, diabetes, diagnosis group, forced vital capacity, functional
status, oxygen need at rest, partial pressure of carbon dioxide, pulmonary artery systolic
pressure, six-minute walk distance), lagged versions of these covariates, time since
waitlist registration, geography, race/ethnicity, gender, blood type, and height as
predictors. This model was fit among individuals who did not receive transplant in the
observed data (i.e., whose waitlist outcome was observed) and applied to all individuals
to obtain (counterfactual) predicted probabilities of pre-transplant survival. These
predicted probabilities were then used to generate hypothetical transplant-free survival
and the corresponding counterfactual waitlist outcomes used in the simulation. Similarly,
the predicted probabilities used to generate post-transplant survival in step (7) were
obtained by fitting a discrete-time pooled logistic regression model with post-transplant
mortality as the outcome and the same covariates listed above as predictors. This model
was fit among individuals who received transplant in the observed data (i.e., whose posttransplant outcome was observed) and applied to all individuals to obtain
(counterfactual) predicted probabilities of post-transplant survival. These predicted
probabilities were then used to generate hypothetical post-transplant survival and the
corresponding counterfactual post-transplant outcomes used in the simulation. This
approach allows individuals’ predicted probabilities of pre- and post-transplant survival to
change over time based on their observed covariate data.
The entire simulation (i.e., steps 1-11, above) was repeated 100 times (due to
computational constraints) to obtain distributions of the Kaplan-Meier estimates and
demographic/clinical characteristics. We also conducted sensitivity analyses in which we
varied the transplant offer rate (e.g., using Poisson means of 3 or 9 offers per day) to
explore how lower or higher offer rates might impact results. Analyses were conducted in
R (R Foundation for Statistical Computing, Vienna, Austria) and Stata (StataCorp LLC,
College Station, TX).
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Results
Observed Analyses
Table 3.1 summarizes the demographic and clinical characteristics of the
complete waiting list population as well as the subset of individuals who received
transplant. In the full waitlist population, covariates were measured at the time of waitlist
registration; among the subset of transplanted individuals, covariates are shown both at
the time of patients’ waitlist registration and at the time they received transplant. In the
full waitlist population, the median waiting time was 57 days (interquartile range, IQR:
16-154 days), 5.7% of these patients died on the waitlist during the two-year follow-up
time, 0.5% died within one year of waitlist registration, and 77.6% received transplant.
Among those who received transplant, the median waiting time was 39 days (IQR: 13102), the median follow-up time after transplant was 199 days (IQR: 68-365), 10.9% died
after transplantation during the two-year follow-up time, and 8.3% died within one year of
transplantation. The distributions of some clinical characteristics differed between the
transplanted group and the full waitlist population. For example, the proportion of
patients in diagnosis group D was higher among transplanted individuals (60.1%)
compared to the full waitlist population (57.4%). Conversely, the proportion of patients in
diagnosis group A was lower among transplanted individuals (25.0%) compared to the
full waitlist population (27.0%). At the time of waitlist registration, the distributions of
continuous mechanical ventilation, functional status, and six-minute walk distance were
comparable among the full waitlist population and among the subset of individuals who
would eventually go on to receive transplant. Conversely, at the time of transplant, a
larger proportion of individuals in the post-transplant group were on continuous
mechanical ventilation (7.7%) compared to the full waitlist population (4.1%); a smaller
proportion of individuals in the post-transplant group required no assistance with daily
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living tasks (5.0%) compared to the full waitlist population (11.3%); and the median
(IQR) six-minute walk distance was somewhat lower among transplanted individuals
(800.0 [445.0, 1059.0] feet) compared to the full waitlist population (880.5 [580.0,
1142.0] feet).
Table 3.1. Demographic and clinical characteristics of the complete waiting list population and the
subset of this population who received transplant
In the full waitlist population, covariates were measured at waitlist registration; among the subset of
transplanted individuals, we display covariates measured at waitlist registration and at transplant.

5354
57.0 (16.0, 154.0)

Post-transplant (at
waitlist registration)
4154
39.0 (13.0, 102.0)

Post-transplant (at
transplant)
4154
---

25 (0.5%)

---

---

288 (5.7%)

---

---

4154 (77.6%)

4154 (100.0%)

---

---

---

199.0 (68.0, 365.0)

-----

-----

346 (8.3%)
420 (10.9%)

185 (3.5%)
953 (17.8%)
522 (9.7%)
636 (11.9%)
878 (16.4%)
110 (2.1%)
438 (8.2%)
312 (5.8%)
180 (3.4%)
684 (12.8%)
456 (8.5%)

160 (3.9%)
680 (16.4%)
405 (9.7%)
534 (12.9%)
675 (16.2%)
67 (1.6%)
334 (8.0%)
251 (6.0%)
126 (3.0%)
528 (12.7%)
394 (9.5%)

160 (3.9%)
680 (16.4%)
405 (9.7%)
534 (12.9%)
675 (16.2%)
67 (1.6%)
334 (8.0%)
251 (6.0%)
126 (3.0%)
528 (12.7%)
394 (9.5%)

2263 (42.3%)
3091 (57.7%)

1594 (38.4%)
2560 (61.6%)

1594 (38.4%)
2560 (61.6%)

4224 (78.9%)
552 (10.3%)
411 (7.7%)
124 (2.3%)
43 (0.8%)

3339 (80.4%)
397 (9.6%)
299 (7.2%)
93 (2.2%)
26 (0.6%)

3339 (80.4%)
397 (9.6%)
299 (7.2%)
93 (2.2%)
26 (0.6%)

1444 (27.0%)
299 (5.6%)
538 (10.0%)
3073 (57.4%)

1038 (25.0%)
182 (4.4%)
436 (10.5%)
2498 (60.1%)

1038 (25.0%)
182 (4.4%)
436 (10.5%)
2498 (60.1%)

2100 (39.2%)
195 (3.6%)
607 (11.3%)
2452 (45.8%)
60.0 (52.0, 66.0)
0.7 (0.7, 0.7)
26.0 (22.0, 29.2)

1702 (41.0%)
157 (3.8%)
474 (11.4%)
1821 (43.8%)
61.0 (52.0, 66.0)
0.7 (0.7, 0.7)
26.0 (22.1, 29.1)

1702 (41.0%)
157 (3.8%)
474 (11.4%)
1821 (43.8%)
61.0 (52.0, 66.0)
0.7 (0.7, 0.7)
25.9 (22.1, 29.0)

Waiting List
Total number of patients (N)
Waiting time (days), median (IQR)
Death on waitlist within 1 year of
waitlist registration
All deaths on waitlist
Removal from waitlist due to
transplant
Follow-up time post-transplant
(days), median (IQR)
Death within 1 year of transplant
All deaths post-transplant
REGION
1
2
3
4
5
6
7
8
9
10
11
GENDER
F
M
RACE/ETHNICITY
White
Black
Hispanic
Asian
Other
DIAGNOSIS
A (Obstructive Disease)
B (Pulmonary Hypertension)
C (Cystic Fibrosis)
D (Pulmonary Fibrosis)
BLOOD TYPE
A
AB
B
O
Age (years), median (IQR)
Bilirubin (mg/dL), median (IQR)
BMI (kg/m3), median (IQR)
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Height (feet), median (IQR)
Cardiac index <2 L/min/m2
Central venous pressure (mmHg),
median (IQR)
Continuous mechanical ventilation
Creatinine (serum) (mg/dL), median
(IQR)
Diabetes
Forced vital capacity % predicted,
median (IQR)
Functional status (none)
Oxygen need at rest (L/min),
median (IQR)
pCO2, median (IQR)
Pulmonary artery systolic pressure
(mmHg), median (IQR)
Six-minute walk distance (feet),
median (IQR)

5.6 (5.3, 5.8)
896 (16.7%)

5.6 (5.3, 5.8)
717 (17.3%)

5.6 (5.3, 5.8)
596 (14.3%)

5.0 (5.0, 8.0)

5.0 (5.0, 8.0)

5.0 (5.0, 8.0)

217 (4.1%)

160 (3.9%)

320 (7.7%)

0.8 (0.7, 1.0)

0.8 (0.7, 1.0)

0.8 (0.7, 1.0)

1074 (20.1%)

895 (21.5%)

971 (23.4%)

48.0 (38.0, 62.0)

48.0 (37.0, 61.0)

45.0 (36.0, 58.0)

604 (11.3%)

472 (11.4%)

209 (5.0%)

4.0 (2.0, 6.0)

4.0 (2.5, 6.0)

4.0 (2.5, 8.0)

43.0 (40.0, 50.0)

43.0 (40.0, 50.0)

45.0 (40.0, 53.0)

38.0 (31.0, 48.0)

38.0 (30.0, 47.0)

38.0 (31.0, 49.0)

880.5 (580.0, 1142.0)

880.0 (562.0, 1146.0)

800.0 (445.0, 1059.0)

Table 3.2 (Figure 3.1) displays the odds ratio estimates (predicted probabilities)
for better versus worse priority under the modified LAS by demographic and clinical
characteristics at each possible offer date. Odds ratios greater than 1 for a given
category indicate that a person in that category is more likely to receive better priority
under the modified LAS relative to a person in the reference category.

Table 3.2. Estimated odds ratios for better versus worse priority under the modified LAS by
demographic and clinical characteristics at each possible offer date

Covariate
Diagnosis A
Diagnosis B
Diagnosis C
Diagnosis D
Age (years) [18,50)
Age (years) [50,59)
Age (years) [59,65)
Age (years) [65,80]
Male
Female
BMI Underweight
BMI Normal
BMI Overweight
BMI Obese
Height (feet) [4.33,5.25)
Height (feet) [5.25,5.50)
Height (feet) [5.50,5.75)
Height (feet) [5.75,6.92]
Blood Type A
Blood Type AB
Blood Type B
Blood Type O
No Previous Transplant
Previous Transplant

Univariable (Unadjusted)
Model
Odds
95% Confidence
Ratio
Interval
REF
1.17*
(1.15,
1.20)
0.14*
(0.13,
0.14)
7.24*
(7.17,
7.32)
REF
N/A
N/A
2.16*
(2.13,
2.19)
1.83*
(1.81,
1.85)
1.39*
(1.38,
1.41)
REF
N/A
N/A
0.81*
(0.81,
0.82)
0.05*
(0.05,
0.05)
REF
N/A
N/A
2.60*
(2.58,
2.63)
3.71*
(3.64,
3.77)
REF
N/A
N/A
1.17*
(1.16,
1.19)
1.27*
(1.26,
1.29)
1.37*
(1.36,
1.38)
REF
N/A
N/A
1.31*
(1.28,
1.33)
1.07*
(1.05,
1.08)
1.11*
(1.10,
1.11)
REF
N/A
N/A
1.46*
(1.40,
1.53)
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Multivariable
(Adjusted) Model
Odds
95% Confidence
Ratio
Interval
REF
0.78* (0.75,
0.81)
0.01* (0.01,
0.01)
13.6* (13.3,
13.8)
REF
N/A
N/A
0.59* (0.58,
0.61)
0.38* (0.37,
0.38)
0.15* (0.14,
0.15)
REF
N/A
N/A
0.83* (0.82,
0.84)
0.01* (0.01,
0.01)
REF
N/A
N/A
1.98* (1.94,
2.01)
2.07* (2.02,
2.12)
Excluded due to
collinearity with BMI
REF
2.02*
0.98
1.07*
REF
0.64*

N/A
(1.94,
(0.96,
(1.06,
N/A
(0.61,

N/A
2.11)
1.00)
1.09)
N/A
0.67)

UNOS Region 1
UNOS Region 2
UNOS Region 3
UNOS Region 4
UNOS Region 5
UNOS Region 6
UNOS Region 7
UNOS Region 8
UNOS Region 9
UNOS Region 10
UNOS Region 11
No Cigarette Use
Cigarette Use
HLA Mismatch (55% missing)
0
1
2
3
4
5
6
Primary Payment Source/Insurance
Private Insurance
Medicaid
Medicare Fee for Service
Medicare & Choice
Children’s Health Insurance Program
Department of VA
Other government insurance
Self
Donation
Free Care
Pending
Foreign Government
Education Level (3% missing)
None
Grade School
High School or GED
Some College
Associate or Bachelor’s Degree
Post-college or Graduate Degree
Employment Status (53% missing)
Not Employed
Employed
Prior Cardiac Surgery (2% missing)
No
Yes
Prior lung surgery (52% missing)
No
Yes
Diabetes
No
Yes
Functional Status
At least some assistance needed
No assistance needed
Cardiac index
≥2 L/min/m2
<2 L/min/m2
Mechanical ventilation
Not continuous
Continuous
Six-minute walk distance
Q1: [0, 656) feet
Q2: [656, 928) feet
Q3: [928, 1160) feet
Q4: [1160, 4000) feet

REF
0.34*
0.45*
0.41*
0.43*
0.42*
0.35*
0.21*
0.38*
0.53*
0.40*
REF
1.00

N/A
(0.32,
(0.44,
(0.39,
(0.41,
(0.40,
(0.34,
(0.20,
(0.37,
(0.51,
(0.38,
N/A
(0.99,

N/A
0.35)
0.47)
0.42)
0.44)
0.44)
0.36)
0.22)
0.40)
0.55)
0.41)
N/A
1.01)

REF
0.24*
0.40*
0.45*
0.44*
0.54*
0.46*

N/A
(0.16,
(0.28,
(0.32,
(0.32,
(0.39,
(0.33,

N/A
0.34)
0.55)
0.63)
0.62)
0.76)
0.64)

REF
N/A
N/A
0.69*
(0.68,
0.66)
0.88*
(0.86,
1.01)
0.67*
(0.66,
0.79)
0.01*
(0.00,
0.03)
0.58*
(0.56,
0.60)
0.97*
(0.94,
1.00)
3.30*
(2.81,
3.87)
drop (perfect prediction)
0.66*
(0.50,
0.87)
19.9*
(10.8,
36.8)
0.84*
(0.80,
0.88)

REF
0.49*
0.56*
0.52*
0.51*
0.38*
0.88*
0.40*
0.39*
0.74*
0.72*
REF
0.91*

N/A
(0.46,
(0.53,
(0.49,
(0.48,
(0.35,
(0.84,
(0.37,
(0.36,
(0.70,
(0.68,
N/A
(0.90,

N/A
0.51)
0.58)
0.55)
0.54)
0.42)
0.93)
0.42)
0.42)
0.79)
0.77)
N/A
0.93)

Excluded due to
missingness

Excluded due to
ambiguity in how to
combine groups to
ensure sufficient
sample sizes for
stable parameter
estimates

REF
1.01
0.96
1.09
1.14
1.67*

N/A
(0.65,
(0.61,
(0.69,
(0.73,
(1.07,

N/A
1.59)
1.51)
1.71)
1.79)
2.63)

REF

N/A

N/A

1.47*

(1.44,

1.50)

REF
1.54*

N/A
(1.51,

N/A
1.57)

REF

N/A

N/A

1.86*

(1.81,

1.92)

REF
0.85*

N/A
(0.84,

N/A
0.86)

REF
2.00*

N/A
(1.97,

N/A
2.04)

REF
3.44*

N/A
(3.37,

N/A
3.52)

REF
21.3*

N/A
(20.0,

N/A
22.7)

REF
1.50*

N/A
(1.49,

N/A
1.52)

REF
3.31*

N/A
(3.24,

N/A
3.38)

REF
1.61*

N/A
(1.55,

N/A
1.67)

REF
18.7*

N/A
(16.5,

N/A
21.1)

REF
2.12*
5.98*
3.00*

N/A
(2.10,
(5.91,
(2.97,

N/A
2.15)
6.05)
3.04)

REF
5.10*
28.6*
7.44*

N/A
(5.01,
(27.6,
(7.28,

N/A
5.18)
29.6)
7.61)
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REF
N/A
N/A
0.69* (0.48,
0.99)
0.43* (0.30,
0.61)
0.49* (0.35,
0.71)
0.43* (0.30,
0.61)
0.55* (0.39,
0.78)
Excluded due to
missingness and
because variable is
not clinically
important
REF
N/A
N/A
1.26* (1.20,
1.32)
Excluded due to
missingness; use
prior cardiac surgery
instead

Creatinine (serum)
Q1: [0.20,0.67) mg/dL
Q2: [0.67,0.80) mg/dL
Q3: [0.80,0.93) mg/dL
Q4: [0.93,6.83] mg/dL
Oxygen need at rest
Q1: [0, 2) L/min
Q2: [2, 3) L/min
Q3: [3, 4) L/min
Q4: [4,35] L/min
Race/Ethnic: White
Race/Ethnic: Black
Race/Ethnic: Hispanic
Race/Ethnic: Asian
Race/Ethnic: Other
Baseline Odds (exp(Intercept))

REF
1.32*
1.58*
1.29*

N/A
(1.31,
(1.56,
(1.27,

REF
N/A
0.88*
(0.86,
0.91*
(0.90,
1.19*
(1.18,
REF
N/A
1.84*
(1.82,
2.73*
(2.67,
1.67*
(1.62,
1.05*
(1.02,
N/A (varies by

N/A
1.34)
1.60)
1.31)

REF
0.47*
0.40*
0.19*

N/A
(0.46,
(0.39,
(0.19,

N/A
0.48)
0.41)
0.20)

N/A
0.89)
0.91)
1.21)
N/A
1.87)
2.79)
1.72)
1.08)
model)

REF
0.98*
1.15*
1.17*
REF
1.34*
1.17*
1.25*
0.66*
4.87*

N/A
(0.96,
(1.14,
(1.15,
N/A
(1.30,
(0.13,
(1.19,
(0.60,
(1.74,

N/A
1.00)
1.17)
1.20)
N/A
1.37)
1.20)
1.32)
0.71)
13.6)

* Statistically significant at the 𝛼 = 0.05 level

Figure 3.1 shows that diagnosis group, six-minute walk distance, continuous mechanical
ventilation, functional status, and age exhibit the largest impact on prioritization changes.
Individuals in diagnosis group D (pulmonary fibrosis) are 13.6 (95% confidence interval,
CI: 13.3-13.8) times more likely to receive better priority under the modified LAS relative
to individuals in diagnosis group A (obstructive diseases); individuals whose six-minute
walk distance falls between 928-1160 feet are 28.6 (95% CI: 27.6-29.6) times more likely
to receive better priority under the modified LAS relative to individuals whose six-minute
walk distance falls between 0-656 feet; individuals receiving continuous mechanical
ventilation are 18.7 (95% CI: 16.5-21.1) times more likely to receive better priority under
the modified LAS relative to individuals who do not require continuous mechanical
ventilation; individuals who require no assistance in daily living tasks are 21.3 (95% CI:
20.0-22.7) times more likely to receive better priority under the modified LAS relative to
individuals who require at least some assistance with these tasks; and the odds of
receiving better priority under the modified LAS decrease as age increases.
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Figure 3.1. Bar charts of the predicted probability of receiving better priority under the modified LAS
compared to the existing one for each covariate individually, after adjusting for all other covariates

In probability terms, individuals in diagnosis group D had an 81.1% probability of
receiving better priority under the modified LAS. Conversely, individuals in diagnosis
group A were almost equally likely to receive better priority (47.2%) versus worse priority
or no change (52.8%) under the modified LAS (Figure 2). Individuals whose six-minute
walk distance fell between 928-1160 feet had the highest probability of receiving better
priority under the modified LAS (76.1%) compared to individuals whose walk distance
fell below or above that range. Individuals receiving continuous mechanical ventilation or
who required no assistance with daily living tasks also had higher probabilities of
receiving better priority under the modified LAS. Finally, the probability of receiving
better priority under the modified LAS also decreased with age.
To quantify the extent to which changes in prioritization are driven by changes in
predicted pre- or post-transplant survival between the modified and existing LAS,
separate generalized r2 statistics were obtained for each panel in these plots, as well as
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overall (Table 3.3). Histograms of the difference between patients’ rank under the mLAS
versus LAS are shown in Appendix 3.1 for reference.

Table 3.3. Generalized r2 values quantifying the extent to which changes in prioritization under the
modified versus existing LAS are driven by changes in predicted pre- or post-transplant survival
Values were obtained from generalized linear mixed models with continuous differences in ranks for
each patient under the modified and existing LAS as the outcome and differences in predicted preand post-transplant survival as predictors.
Difference in
Predicted Survival

Lower Priority

Higher Priority

Pre-transplant

0.144 (0.142, 0.147)

0.215 (0.212, 0.217)

Post-transplant

0.028 (0.027, 0.030)

0.100 (0.098, 0.101)

Pre-transplant

0.498 (0.494, 0.501)

0.249 (0.245, 0.254)

Post-transplant

0.067 (0.064, 0.069)

0.248 (0.244, 0.253)

Pre-transplant

0.049 (0.043, 0.055)

0.268 (0.257, 0.279)

Post-transplant

0.033 (0.028, 0.038)

0.020 (0.016, 0.024)

Pre-transplant

0.239 (0.233, 0.245)

0.184 (0.166, 0.201)

Post-transplant

0.064 (0.060, 0.068)

0.088 (0.075, 0.103)

Pre-transplant

0.018 (0.016, 0.021)

0.294 (0.291, 0.297)

Post-transplant

0.006 (0.005, 0.008)

0.085 (0.083, 0.087)

Six-minute walk Q1:
[0, 656) feet

Pre-transplant

0.039 (0.037, 0.042)

0.244 (0.238, 0.250)

Post-transplant

0.024 (0.022, 0.026)

0.025 (0.022, 0.028)

Six-minute walk Q2:
[656, 928) feet

Pre-transplant

0.227 (0.222, 0.232)

0.198 (0.193, 0.202)

Post-transplant

0.045 (0.049, 0.042)

0.127 (0.123, 0.131)

Six-minute walk Q3:
[928, 1160) feet

Pre-transplant

0.091 (0.086, 0.097)

0.280 (0.276, 0.285)

Post-transplant

0.073 (0.068, 0.079)

0.203 (0.199, 0.207)

Six-minute walk Q4:
[1160, 4000) feet

Pre-transplant

0.349 (0.343, 0.355)

0.207 (0.202, 0.211)

Post-transplant

0.029 (0.026, 0.032)

0.159 (0.154, 0.163)

Model

Covariate

Overall

---

Diagnosis Group A

Diagnosis Group B
Stratified
Diagnosis Group C

Diagnosis Group D

Stratified

In both the worse and better priority subsets, changes in predicted pre-transplant
survival explained a greater proportion of the variability in differences in rank than
changes in predicted post-transplant survival. Among individuals who received worse
priority under the modified LAS, changes in predicted pre-transplant survival accounted
for 14.4% of the variability in differences in rank, while changes in predicted post56

transplant survival accounted for 2.8% of this variability. Similarly, among individuals
who received better priority under the modified LAS, changes in predicted pre-transplant
survival accounted for 21.5% of the variability in differences in rank, while changes in
predicted post-transplant survival accounted for 10.0% of this variability. This pattern
was observed for most of the analyses that stratified by diagnosis group and six-minute
walk distance, with one notable exception: for individuals in diagnosis group A who
received better priority, changes in predicted post-transplant survival accounted for
nearly the same proportion of variability in differences in rank (i.e., 24.8%) compared to
changes in predicted pre-transplant survival (i.e., 24.9%).

Simulation Study
Across all scenarios, 31.1% of records, on average, had their LAS and mLAS
scores interpolated due to simulated death dates exceeding patients’ last observed visit
dates. Our reference simulation involved 364 offer dates and a transplant rate of
approximately 6 offers per day, as this rate mimics current donor capacity. Kaplan-Meier
estimates of one-year pre-transplant (waitlist) survival, one-year post-transplant survival,
and one-year overall survival among all individuals appear in Figure 3.2A. Waitlist
survival improved under the modified LAS compared to the existing one, with a median
difference of 1.28% (interquartile range, IQR: 0.52%-2.43%). In a waitlist population of
1000 individuals, this result translates into 12.8 (IQR: 5.2-24.3) fewer waitlist deaths per
year under the modified LAS compared to the existing one. Post-transplant and overall
survival remained comparable across models.
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A

B

Figure 3.2. Survival estimates under the reference simulation (6 offers per day)
Kapan-Meier estimates of one-year pre-transplant (waitlist) survival, one-year post-transplant
survival, and one-year overall survival from the reference simulation (i.e., 6 offers per day) for the
overall simulated population (A) and the discordant set (B).

The majority (84.4% [IQR: 83.9%-84.9%]) of individuals received hypothetical
transplant under both LAS models. Among the subset of individuals (15.6% [IQR:
15.1%-16.1%]) to whom organs were differentially allocated under the modified LAS
(discordant set), the median difference in waitlist survival was 6.89% (IQR: 2.46%11.5%) (Figure 3.2B). Overall survival in the discordant set appears slightly more
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favorable under the modified LAS as well, with a median difference of 2.52% (IQR:
0.90%-4.16%). In a population of 1000 transplanted individuals, these results imply that
844 (IQR: 839-849) of these individuals would be the same under the two LAS models,
but the remaining 156 (IQR: 151-161) individuals would differ. That is, in 156 (IQR: 151161) instances, the modified LAS selects a different person for transplant than the
existing LAS. Among these differentially transplanted individuals, 68.9 (IQR: 24.6-115.0)
fewer waitlist deaths and 25.2 (IQR: 9.0-41.6) fewer overall deaths occur per year under
the modified LAS compared to the existing one. Demographic and clinical characteristics
of individuals in the discordant set appear in Figure 3.3.
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Figure 3.3. Distributions of demographic and clinical characteristics of the discordant set from the
reference simulation (6 offers per day)

Increasing or decreasing the transplant rate (to 9 or 3 offers per day,
respectively) did not substantially change our results (Figures 3.4 and 3.5). However, the
concordance index and Kaplan-Meier estimates of waitlist survival are both higher under
the “high” transplant rate scenario compared to the “low” transplant rate scenario,
consistent with the fact that a much larger proportion of our simulated population is
transplanted in the “high” scenario. For example, in the “high” transplant rate scenario,
91.4% (IQR: 91.2%-91.7%) of individuals received hypothetical transplant under both
LAS models, whereas in the “low” transplant rate scenario, the median concordance was
only 73.2% (IQR: 72.5%-23.8%). Similarly, in the “high” transplant rate scenario, the
median (IQR) Kaplan-Meier estimates for waitlist survival under the existing and
modified LAS were 87.3% (80.4%-89.8%) and 89.7% (85.9%-91.4%), respectively.
Conversely, in the “low” transplant rate scenario, the median (IQR) Kaplan-Meier
estimates for waitlist survival under the existing and modified LAS were 83.0% (78.9%85.2%) and 84.2% (80.1%-86.3%), respectively.
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B

Figure 3.4. Survival estimates under the high transplant rate simulation (9 offers per day)
Kapan-Meier estimates of one-year pre-transplant (waitlist) survival, one-year post-transplant
survival, and one-year overall survival from the high transplant rate scenario (i.e., 9 offers per day)
for the overall simulated population (A) and the discordant set (B).
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Figure 3.5. Survival estimates under the low transplant rate simulation (3 offers per day)
Kapan-Meier estimates of one-year pre-transplant (waitlist) survival, one-year post-transplant
survival, and one-year overall survival from the low transplant rate scenario (i.e., 3 offers per day) for
the overall simulated population (A) and the discordant set (B).
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Discussion
In this study, we used observed and simulated data to examine the clinical
impact of a modified LAS score designed to mitigate selection bias. We found that
changes in prioritization were more pronounced for patients with certain demographic
and clinical characteristics, such as diagnosis group (individuals in group D were more
likely to receive better priority), six-minute walk distance (individuals in the third quartile
of walk distance had the highest probability of receiving better priority), continuous
mechanical ventilation (individuals receiving continuous mechanical ventilation were
more likely to receive better priority), and functional status (individuals who required no
assistance in daily living tasks had a higher probability of receiving better priority).
Changes in predicted pre-transplant survival tended to explain a greater proportion of
the variability in differences in rank than changes in predicted post-transplant survival.
Simulations suggest that one-year waitlist survival may improve slightly under the
modified LAS relative to the existing one, whereas one-year post-transplant and overall
survival remain comparable under the two models. Among individuals who received
hypothetical transplant under one LAS but not the other, waitlist and overall survival
appears more favorable under the modified LAS; post-transplant survival remains similar
to that under the existing LAS.
The fact that changes in prioritization under the modified LAS may be more
pronounced for some patients but not others is clinically relevant, as it implies that
implementation of the modified LAS could lead to important differences in allocation. For
example, individuals in diagnosis group D (pulmonary fibrosis) – who tend to be sicker
and unable to wait long for transplant – had an 81.1% probability of receiving better
priority under the modified LAS (Figure 3.1). Conversely, individuals in diagnosis group
A (obstructive diseases) – who tend to survive longer without transplant, albeit with lower
quality of life – were almost equally likely to receive better priority (47.2%) versus worse
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priority or no change (52.8%) under the modified LAS. Moreover, for individuals in
diagnosis group A who received better priority, changes in predicted post-transplant
survival accounted for nearly the same proportion of variability in differences in rank (i.e.,
24.8%) compared to changes in predicted pre-transplant survival (i.e., 24.9%). Such
observations suggest that while improvements in the prediction of waitlist urgency tend
to have the largest impact on patient prioritization, changes in the prediction of posttransplant survival can impact prioritization for some subgroups of patients. This result is
important to consider, especially as the transplant community continues to debate the
role that post-transplant survival should play in organ allocation (Kasiske et al., 2020;
Maxwell et al., 2014).
With regards to six-minute walk distance, continuous mechanical ventilation,
functional status, and age, our analyses indicate that after adjusting for other covariates,
younger, healthier individuals may have a higher probability of receiving better priority
under the modified LAS compared to older, frailer individuals. These results are
consistent with recent research advocating for more transparency around the impact of
age and frailty on pre- and post-transplant survival (Blumenthal et al., 2017; Schaenman
et al., 2020). Such findings could also help inform discussions on what role these factors
should play in organ allocation (Persad et al., 2009; Veatch & Ross, 2015).
Our simulation study demonstrated that the modified LAS may yield modest
improvements in waitlist survival. The extent of improvement in waitlist survival was
larger among the subset of individuals to whom organs were differentially allocated
under the modified LAS. These findings suggest that alternative organ allocation
schemes can confer as much or more survival benefit to patients as the existing LAS.
However, they also imply that evaluating the performance of allocation systems solely
based on survival might not capture the full extent of transplant benefit. This observation
is consistent with literature calling for greater emphasis on quality of life when evaluating
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the risks and benefits of transplantation (Finlen Copeland et al., 2013; Singer et al.,
2015; Yusen, 2009).
Our study has some limitations. First, the GLMM approach we took to estimate
the proportion of variability (r2) in the differences in rank explained by changes in
predicted pre- versus post-transplant survival does not account for the correlation among
differences in rank. We mitigated this issue by splitting the data into worse-priority and
better-priority subsets, and fitting separate GLMMs to each subset. However, future
methodologic research is needed to extend generalized r2 statistics to the situation
where the outcome of interest is differences in ranks (e.g., perhaps by building off of
transformation approaches commonly used in genetics studies, such as (Beasley et al.,
2009)). Second, while we used observed data to compare the order in which patients
were prioritized under the two LAS models and examined the demographic and clinical
characteristics of patients who received better priority under the modified LAS relative to
the existing LAS, we cannot know whether patients who died on the waitlist under the
existing LAS would, in fact, have received transplant had the modified LAS been used
instead. This limitation motivated us to conduct the simulation study where we examined
how patients’ waitlist and post-transplant survival might change if the modified LAS were
implemented in clinical practice. Limitations of this simulation include a simplified
allocation policy based on blood type and region only (i.e., ignoring other salient, but
difficult to measure, factors to organ matching, such as donor/recipient size and
sensitization, donor organ quality and acceptance criteria, and travel constraints that
arise when delivering donor organs to transplant candidates). Future work should aim to
incorporate these additional factors into the simulation to see how the modified LAS
might perform in more realistic settings.
Overall, this study demonstrates that implementing a modified LAS that mitigates
selection bias into clinical practice can lead to important differences in allocation and
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possibly modest improvement in one-year waitlist survival, without adversely affecting
one-year post-transplant or overall survival. These findings can inform ongoing efforts to
modify lung allocation policy, such as the continuous distribution model.
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CHAPTER 4. A CONCEPTUAL MODEL FOR SOURCES OF SELECTION BIAS IN
LUNG TRANSPLANT ALLOCATION

This chapter is under review. The suggested citation is:
Schnellinger EM, Cantu E, Kimmel SE, Szymczak JE. A Conceptual Model for Sources of
Differential Selection in Lung Transplant Allocation (under review).
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Abstract
Background. In the U.S., donor lungs are allocated to transplant candidates based on
the lung allocation score (LAS). However, additional factors beyond the LAS can impact
who is transplanted, including referral, listing, and donor organ acceptance practices.
These factors can result in selection bias, undermining the fairness of lung allocation.
Yet they have not been systematically studied using formal qualitative methods.
Methods. We conducted a semi-structured qualitative interview study of lung transplant
surgeons and pulmonologists in the U.S. between June 2019 and June 2020 to
understand the role that the LAS plays in clinical decision making, how transplant
clinicians think about selection bias in lung allocation, and whether they feel the LAS
should be modified to account for such bias.
Results. Our 51 respondents (30 transplant surgeons and 21 pulmonologists) identified
many sources of selection bias arising at several points along the pathway from referral
to transplantation. We developed a conceptual model synthesizing these sources of
selection bias into five factors: 1) transplant center’s level of risk tolerance and
accountability, 2) successfulness and fairness of the LAS in mitigating selection bias, 3)
donor organ availability and regional competition, 4) patient health versus program
health, and 5) access to care versus responsible stewardship of organs.
Conclusions. Our conceptual model demonstrates how selection bias can arise
throughout lung transplantation and can facilitate further study of such bias. As the
transplant community continues to develop and implement new allocation models for
lungs and other organs, the sources of selection bias described here should be
considered carefully to ensure that the resulting allocation scheme is more equitable.
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Background
In May 2005, the Organ Procurement and Transplantation Network (OPTN)
implemented a new allocation policy that allocates donor lungs to candidates based on a
lung allocation score (LAS) (Egan et al., 2006; Gottlieb, 2017; U.S. Department of Health
and Human Services, October 20, 1999; United Network for Organ Sharing, 2015). The
LAS is calculated as the difference in days of life between transplant benefit and waiting
list urgency, and is normalized so that it ranges from 0 to 100, with higher values
indicating greater priority for lung transplantation (Egan et al., 2006; United Network for
Organ Sharing, 2015). This score was intended to balance equity, justice, beneficence,
and utility in lung allocation (Gottlieb, 2017; Veatch & Ross, 2015). However, additional
factors beyond the LAS can impact which patients are selected for – and ultimately
receive – transplant, including the timing of referral (Weill et al., 2015) and geographic,
gender, or racial/ethnic disparities in waitlist registration (Mooney et al., 2018; RossDriscoll et al., 2020; Thabut et al., 2012; Wille et al., 2013), pre- and post-transplant
survival (Egan & Edwards, 2016; Maxwell et al., 2014; Russo et al., 2011), and donor
organ availability (Benvenuto et al., 2018; Drolen et al., 2020; Ross-Driscoll et al., 2020).
Collectively, such factors can give rise to selection bias, which occurs because
individuals are removed from the waitlist upon receipt of transplant, and because in
order to receive transplant, individuals must survive long enough for a suitable donor
organ to become available (Glymour & Greenland, 2008; Schnellinger et al., 2021). Such
bias can undermine the fairness of organ allocation.
While much statistical research has been conducted surrounding the LAS and
selection bias (Schnellinger et al., 2021; Vock et al., 2017; Vock et al., 2013; Xiang &
Murray, 2012), less is known about how lung transplant surgeons and pulmonologists
employ the LAS in practice, or how these clinicians interpret and respond to selection
bias. A few qualitative studies have examined candidate (Blumenthal et al., 2017; Volk et
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al., 2011) and organ selection (Loss et al., 2013); however, these studies focused almost
exclusively on the patient screening/evaluation phase of transplantation, rather than the
complete pathway from referral through transplantation.
Given that OPTN is currently developing a new organ allocation framework – the
continuous distribution model (Kasiske et al., 2020; Snyder et al., 2018; U.S. Department
of Health & Human Services) – and that this new framework is planned to be
implemented in lung transplantation followed by other organs (e.g., kidney, liver, heart),
it is important to develop a thorough understanding of where selection bias can arise in
the current lung allocation system and how such bias can impact the successfulness and
fairness of lung allocation. Synthesizing such information into a conceptual model can
facilitate further study of the patient- and program-level effects of selection bias in lung
transplantation. Toward that end, we conducted a qualitative study of lung transplant
surgeons and pulmonologists between June 2019 and June 2020 to understand the role
that the LAS plays in clinical decision making, how transplant clinicians think about
selection bias in lung allocation, and whether they feel the LAS should be modified to
account for such bias.

Methods
Study Design and Target Population
We conducted a qualitative study between June 2019 and June 2020 to
understand the role that the Lung Allocation Score (LAS) plays in clinical decision
making. Our target population consisted of lung transplant surgeons and pulmonologists
practicing in the United States. The study protocol was reviewed by the University of
Pennsylvania Institutional Review Board (IRB Protocol #833089) and determined to
meet exemption criteria authorized by 45 CFR 46.104, category #4,2. We also followed
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the Consolidated criteria for Reporting Qualitative Research (COREQ) checklist (Tong et
al., 2007) (see Appendix 4.1).

Participants and Recruitment
Participants were recruited through the “Pulmonology and
Cardiothoracic/vascular surgery” listserv of the International Society for Heart and Lung
Transplant (ISHLT). Individuals were included in our study if they were lung transplant
surgeons or pulmonologists practicing in the United States; individuals who did not
practice in the United States, were still in training (e.g., medical student or resident), or
who focused on other organ transplant (e.g., heart) were excluded. Eligible individuals
were invited to participate via email by the lead author who has training in qualitative
methods (EMS). We purposively sampled individuals to introduce variation by discipline
(lung transplant surgeon or pulmonologist), and also sought to include respondents with
diverse characteristics relevant to our study question (e.g., geography, years in
practice). The lead and senior author (JES, a sociologist with expertise in qualitative
methods) monitored for thematic saturation during the data collection period to
determine sample size adequacy. We maintained a data collection memo where key
concepts were recorded following each interview. A saturation grid based on the
interview guide was created to track the emergence of novel themes across respondents
(Brod et al., 2009). Recruitment continued until thematic saturation across the main
domains of our interview guide was reached (Miles et al., 1994; Miles et al., 2014;
Weiss, 1994).

Data Collection
Interviews were conducted either in-person or by phone by the lead author using
a semi-structured guide (see Appendix 4.2). The interview guide was piloted and
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questions refined to ensure complete capture of relevant concepts, comprehension of
questions, and length. The final guide included questions in the following domains: 1)
how lung transplant surgeons and pulmonologists use the LAS in clinical practice; 2)
factors which clinicians deem important for prioritizing lung transplant patients, but which
might not be captured by the LAS; 3) how clinicians think about selection bias in lung
allocation; and 4) whether clinicians think the LAS should be modified to account for this
bias, and if so, how. Participants consented verbally and gave permission for their
interview to be recorded.

Analyses
Interviews were professionally transcribed, de-identified, and uploaded to NVivo
qualitative data analysis software (NVivo Release 1.0, QSR International 2020,
Doncaster, Australia) for analyses. Data were analyzed by two authors (EMS, JES) in
consultation with the research team using a modified Framework Method (Gale et al.,
2013). Analysis proceeded in four phases. First, interview transcripts and data collection
memos were reviewed to create an index codebook (Deterding & Waters, 2021).
Second, the index codebook was applied to the transcripts line-by-line. The index
codebook was open to revision as patterns emerged in the data, and existing codes
were further developed into subcodes. Revisions to the codebook were performed in
consultation with the research team and discrepancies were resolved by consensus.
Third, once the transcripts were coded we charted the data into a framework matrix,
exploring overlapping codes and comparing themes within and across respondents. At
this stage we confirmed that thematic saturation was reached both overall and within
subgroups defined by discipline (transplant surgeon, pulmonologist) (Gale et al., 2013).
Fourth, we developed a conceptual model for sources of selection bias based on the
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framework matrix. The model was refined through discussions amongst the research
team and negative case analysis.
Self-reported respondent characteristics, including gender, race/ethnicity, years
of experience, and UNOS region, were ascertained at the end of each interview and
summarized using counts (proportions) or medians (interquartile ranges), as appropriate
(STATA 15, StataCorp LLC, College Station, TX, USA).

Results
Respondents
Email invitations were sent to 218 potential respondents, with 76 (35%)
responding. Of the 76 total individuals who responded, 19 declined to participate, 4 did
not meet our study’s inclusion/exclusion criteria (e.g., they were still in training or
focused on heart transplant), and 2 did not respond to follow-up emails to schedule an
interview. We interviewed the remaining 51 participants (30 [59%] pulmonologists and
21 [41%] lung transplant surgeons). The majority of participants were male (84%), white
(61%), and had practiced at more than one institution (55%), with a median duration of
experience of 15 years (Table 4.1).

Table 4.1: Demographic characteristics of interview respondents
Factor
N
Gender
Female
Male
Race/ethnicity
African American
Asian/Indian
Hispanic/Latino
Other
White
Discipline
Pulmonologist
Transplant Surgeon
UNOS Region
1
2

Value
51
8 (16%)
43 (84%)
4 (8%)
6 (12%)
7 (14%)
3 (6%)
31 (61%)
30 (59%)
21 (41%)
1 (2%)
18 (35%)
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3
4
5
6
7
8
9
10
11
Prior institution
Years of experience [median (IQR)]
Began practice before LAS was implemented

5 (10%)
1 (2%)
3 (6%)
1 (2%)
5 (10%)
2 (4%)
2 (4%)
5 (10%)
8 (16%)
28 (55%)
15.0 (9.0, 20.0)
24 (47%)

Sources of Selection Bias Along the Lung Transplantation Pathway
In each of the sections below, we describe a step along the transplantation
pathway where respondents identified that selection bias might arise. These sources of
selection bias are supported by exemplar quotes and mapped to five overarching
concepts (as explained further in the Conceptual Model section).

Referral
Respondents identified several time points at which selection bias influences
lung transplantation. First, they identified referral to a transplant center. However,
because lung transplant surgeons and pulmonologists are not typically involved at this
stage of the process, respondents had less to say about the way selection bias shapes
referral. That said, some respondents suggested that referring patterns depend on how
knowledgeable patients and their primary pulmonary providers are about transplantation:
“At some point, a physician, sometimes at [hospital] but sometimes in the
community, decides that a patient’s lung disease is advanced enough to be
referred to [transplant center] for transplant evaluation. […] So there’s this prescreening step that happens way before we even meet some of these patients”
[pulmonologist].
Other respondents advocated for more data on patients who are referred to a transplant
center, but ultimately not listed:
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“I think something that doesn't get captured very well by research though is how
many people present for evaluation for a transplant and then pass away.
Because there's many people that may present for evaluation that we turn down
or get deactivated and that's not necessarily captured very well. It would be
interesting if [the UNOS] registry could be something that captured that as well,
like captured all people that were considered for lung transplant. Whereas right
now it only is capturing people that actually go on to undergo a transplant. So
you know, there's no national registry that captures all patients who present for
evaluation. And so while it may capture people that die on the waitlist, it doesn't
capture any of the people that were deemed not to be good candidates for
transplant so that were never listed.” [pulmonologist]
Such data could help clarify the role selection plays in referral processes.

Screening and Waitlist Registration
Respondents identified the transition between transplant screening/evaluation
and waitlist registration as the second major source of selection bias after referral. The
screening/evaluation process involves a series of evaluations conducted by the
transplant center – including assessments of physical and mental health and
consideration of social and financial support – to determine whether a particular patient
is sick enough to be registered on the waitlist yet healthy enough to withstand transplant,
and whether the patient has sufficient social and financial support to undergo such a
major procedure. Several respondents referred to this timeframe as the patient’s
“transplant window”, and described how patients listed too early or too late with respect
to this window may have a difficult time finding a suitable donor organ match and
receiving transplant. While professional societies and consensus documents provide
guidance to the lung transplant community as to the appropriate timing of – and criteria
for – listing patients, respondents suggested that listing decisions ultimately come down
to clinician judgment and subjective impression:
“I think you're interpreting somebody's capabilities [of surviving transplant] based
on how they look and how robust are they and do they look frail and those types
of things which I think are one reflector of survival that kind of goes into the
gestalt when you see someone. Part of that assessment is do they look like
they're about to keel over or not? And I think there's some patients where that
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probably is accurate and there are some patients where it's really not.”
[pulmonologist]
Bias can also come into play more subtly when evaluating patients’ extent of social and
financial support, their level of adherence with protocols, and how that might impact their
transplantation outcomes:
"The atrial pressure of your heart, that’s hard data; your PFTs [pulmonary
function tests] are hard data. So [selection committees] shouldn't be biased about
how sick your heart is, or how sick your lungs are, but there is a lot of bias
regarding how good of a...how compliant you're gonna be with your medications;
what kind of family support you have; what is the level of outside, your stress, on
how you're gonna manage to take care of yourself after transplant? And
sometimes you can say, ‘Well, you know what? This patient might survive a
transplant, but they will [be on] chronic pain medications, or taking painkillers, or
at some point they smoke marijuana, or at some point...’ So, you know, all those
factors come into play, particularly from the social aspects, which are the most
difficult to define. And how do you define those in a way that you don't stigmatize
your patient, and you eventually don't provide them with an opportunity.”
[surgeon]
Respondents suggested that listing decisions are also influenced by a transplant
center's level of risk tolerance within the context of accountability-promoting regulatory
pressures. Decisions about individual patients are made with the center’s “numbers”
(e.g., average one-year post-transplant survival calculated by the Scientific Registry of
Transplant Recipients [SRTR] and acceptable performance thresholds determined by
UNOS and/or Centers for Medicare & Medicaid Services [CMS] to monitor program
performance) in mind.
“I guess the fact that we do 80, 90 transplants per year allows us to reason…
well, given the number, we can be a little more aggressive and try to help these
[high-risk] patients, which in a smaller center, probably that would give them a
bigger hit on their overall numbers. I guess our center, we're large enough, and
also experienced enough not to make a strong decision [for or against listing a
particular patient].” [surgeon]
Programs with larger transplant volumes may have more experienced surgical teams
and increased access to medical technology (e.g., extracorporeal membrane
oxygenation) which may enable them to manage high-risk patients more easily. This
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perception of program capacity and expertise was understood by our respondents as
one potential influence on decision-making:
“Everything has some bias involved, bias of the treatment team, bias of the
center treating, how big your program is, how experienced are your surgeons,
what is your workforce, and what can you take care of, because the same patient
can be looked after in a different center [and] based on how they can do things
there and the complexity of the patient, if they're used to dealing with better,
maybe they can pull it off as opposed to a center which is not used to doing that
many transplants or it doesn't have the facility to do that. So I think the bias does
exist in one way or the other based on available resources and experience of that
center.” [surgeon]
Additionally, their large transplant volume effectively dilutes the impact that poor patient
outcomes might have on their program’s pre- or post-transplant survival metrics:
“The other half of that is in when it comes to candidates, I think there is an
awareness of what our current kind of mortality and waitlist statistics are as to
whether we're really capable of absorbing a really high-risk candidate. So we're a
really aggressive center I think compared to other centers too. But even at a
certain point, if you've had a string of bad outcomes or if you've had some waitlist
deaths and somebody comes up to the [listing] committee who is a marginal
candidate who has the potential to have a bad outcome, depending on where the
program is, I think we have to take a harder look at that case and say like, can
we absorb another bad outcome in those case? So I think there's a perception
that it affects both candidates and recipients.” [pulmonologist]
Thus, it was explained that large-volume centers are perceived to have greater flexibility
when choosing which patients to register on their waiting list, whereas small-volume
centers may be forced to be more selective in order to promote the continued well-being
of their program.

Waitlist Registration and Waiting Period
The third major source of selection bias identified by respondents occurs
between the waitlist registration and waiting period phases in the patient pathway. This
part of the pathway is ostensibly determined by the LAS score, which was designed to
facilitate lung allocation by prioritizing patients for whom transplant benefit (i.e., posttransplant survival minus pre-transplant survival) exceeds waitlist urgency (i.e., pre78

transplant survival); equivalently, the LAS prioritizes individuals for whom post-transplant
survival minus two times pre-transplant survival is favorable. In practice, the LAS
determines the order in which patients receive donor organ offers as well as the number
and quality of offers they receive, with higher-LAS patients having “first bid” [surgeon] on
donor organ offers. Since the score itself is calculated based on patients’ demographic
and clinical characteristics, some respondents viewed the LAS as a “byproduct”
[pulmonologist] that reflects patients’ medical urgency, but does not on its own influence
providers’ decisions to register patients on the waitlist or transplant them:
“The score is something that I think we're all cognizant of in the back of our
minds, but it's not necessarily a factor to say someone should or shouldn't be a
candidate. Because the LAS is almost a byproduct, right? Someone has to be a
transplant candidate, then they get the LAS score for whatever it is […] The LAS
will be just whatever it is based on the specific tests of that patient.”
[pulmonologist]
Some respondents lauded the LAS’s ability to update as patients become sicker, thereby
ensuring that patients receive more donor organ offers as their waitlist urgency
increases, and hence, mitigating survivor bias (especially relative to the previous firstcome, first-serve system of lung allocation):
“if someone's disease advances and they end up on mechanical ventilation or
something like that, their LAS goes through the roof and they're going to get an
organ. So in many ways, the LAS mitigates survivor bias” [pulmonologist].
Other respondents, however, suggested that the LAS is imperfect, mitigating
some – but not all – sources of bias. Specific concerns include: 1) the LAS score’s
reliance on predicted one-year pre- and post-transplant survival, which may not be as
relevant to patients or clinicians as longer term (e.g., three- or five-year) survival or
quality of life; 2) the LAS score’s failure to include variables important for predicting
survival among some diagnosis groups but not others (e.g., FEV1 is clinically relevant
for some diagnoses, but not statistically significant across all diagnoses); and 3)
discrepancies in LAS among patients who are dual-listed at multiple centers.
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These perceived “gaps” [pulmonologist] in the LAS led many respondents to
question the fairness of lung allocation for particular patients. One respondent described
being more concerned about survivor bias for patients with low LAS than for patients
with high LAS scores, as the former tend to remain on the waitlist behind the latter,
eventually becoming too old or sick to receive transplant:
“Yeah, it [survivor bias] is a concern. And it actually is a concern that I primarily
have in regards to patients that have a relatively low score at the time of listing,
especially patients with emphysema. You know, since the Lung Allocation Score
favors patients with interstitial lung disease, patients with emphysema usually get
a lower score. And we certainly have a number of patients on our waitlist where I
kind of wonder are they ever going to get lungs? And, you know, are they
eventually going to be too old, or are they going to develop comorbidities that
would prevent them from being suitable for transplant anymore?” [pulmonologist]
The challenge of advocating for patients within the existing LAS framework can lead to
differences in patient management practices – including decisions to de-list patients –
across centers.
These differences led some respondents to voice concerns about the potential
for gaming, or the use of tactics that exploit the ambiguity and flexibility of the LAS to
achieve desired outcomes while ostensibly honoring the framework. Overall, two broad
types of gaming were identified by our respondents: 1) patient-level: manipulating a
specific patient’s LAS to increase their chances of receiving transplant by capitalizing on
“system inefficiencies” [pulmonologist] (e.g., variables that are open to clinical
interpretation, and thus can be changed while maintaining honesty); and 2) programlevel: avoiding transplanting patients with the highest LAS or being more conservative
with which donor organs one accepts to ensure that program-level accountability metrics
are maintained.
The first type of gaming was described as patient advocacy, where clinicians
worked to ensure that patients receive the score which truly reflects their waitlist
urgency:
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“Everybody is trying to get an angle for their own patients, you know, everybody
feels responsible to find a strategy for their patient to get the transplant. So,
they're gonna think of things that they can do that are, in general, are almost
always I think are honest and have integrity. I don't think people cheat in any
substantial degree, I guess, but they will use every honest angle that is available.
We see that in all of our lists. But that's what you want your doctor to do for you,
right? We assume that we'll be audited, so anything we do we want to be able to
justify and explain why or that we were completely honest with how we did it.”
[surgeon]
Having the flexibility to update patients’ LAS as their clinical condition changes was seen
as a positive attribute of the LAS. All respondents said that changes in patients’ LAS
must be supported by documentation because centers are subject to site visits and/or
audits from UNOS, CMS, and insurance companies. However, respondents mentioned
that the guidelines around some variables are vague (e.g., how much oxygen to use for
six-minute walk test) and may even have conflicting goals (e.g., the walk test is used to
assess both the severity of the patient’s disease and the patient’s ability to withstand the
transplant procedure). If centers have enough resources, they are able to conduct such
tests multiple times to fulfill all goals, but if not, some sort of compromise must be made:
“At [previous transplant center] we had this requirement that you had to be able
to walk 1000 feet in 6 minutes to qualify for listing. So we would give them as
much oxygen as they needed it and we would push them to walk really far. And
then when they changed the LAS algorithm and we saw, like, all...that, like, these
patients, these people who are really, really sick, with really advanced lung
disease, their scores went down significantly and we weren't getting offers for
them anymore, then we had to change how we did it. And we had the resources
there to say, ‘Okay, we're going to do an LAS six-minute walk test,’ which is
where we did a six-minute walk test based on their resting oxygen requirements.
But then we would continue to do a six-minute walk test to assess their functional
capacity. And so we would have both pieces of information, which was helpful,
and then we'd use the LAS six-minute walk to put into a unit. Here, we don't have
those kinds of resources to be doing it twice. And so we just accept the fact that,
well, we do it on something sort of in the middle and try to interpret the data as
best we can.” [pulmonologist]
Respondents also acknowledged that it can sometimes be difficult to distinguish
between acceptable and unacceptable patient management strategies:
“it’s hard to define where gaming the system versus differences in management
practices, where that line is drawn” [surgeon].
81

In general, respondents supported the idea of exception requests, which allow
physicians to petition UNOS to increase a particular patient’s score when the LAS does
not seem to accurately capture the severity/urgency of the patient’s clinical condition.
That said, respondents expressed frustration at the inconsistency with which certain
appeals are evaluated (appeals are reviewed by a rotating board of clinicians, and
acceptance criteria vary). Some respondents also expressed concern that dual-listed
patients did not always have the exact same LAS in each transplant center (this
observation was attributed to lack of communication/data sharing among transplant
centers, rather than intentional dishonesty). Inconsistencies in LAS, while not
necessarily indicative of gaming, were still viewed as having considerable impact on
donor organ sharing, as even small differences in LAS can pull donor organs from one
center to a different one:
“I think the [LAS] score is reasonable, but how people populate their lists is very
variable, and my concern is that people lean on the score as being a vetted,
objective, consistent measure of priority, and it's not. People will use different
variables to their advantage, and listing practices are so variable that we can't
assume that an LAS of 40 means the same thing at different centers. In fact,
we've seen patients who go to different centers have very different lung allocation
scores. And when you have variability in interpretation of how to score someone,
it makes then the concept of broader regional sharing grossly unfair and
vulnerable to gaming. This big push for broader regional sharing has to be
predicated upon making listing behaviors entirely consistent across the country,
or there will be gross iniquities manifest.” [surgeon]
The second type of gaming was conceptualized by our respondents as advocacy
on behalf of a program. Selectivity when making listing decisions ensures that the
program does not take on patients who are too high-risk for the transplant team to take
care of (e.g., due to the technical skills of their transplant team or the amount of
technological resources they have to support patients). While selectivity in listing could
be viewed as “cherry picking” [surgeon], most respondents felt that selectivity is
sometimes necessary to preserve the integrity of the program and ensure that the
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program’s ratings do not fall below UNOS/CMS’s acceptability thresholds. However,
three respondents – all surgeons – suggested that larger programs may have enough
resources to operate a “substitute” or back-up list in which individuals who are not
currently sick enough for official listing are monitored until they become sick enough.
The problem with this approach arises when the substitute list is not shared with UNOS,
as then programs can adjust the size of their waitlist to manipulate their program-level
transplant rate:
“Well, the [program-level] metrics are grossly imperfect. And the reason is that
there are centers that will only list one patient who is size and blood type available
in a given range, a given sort of size and blood type parameters. We don't do that.
So we...if someone meets criteria, and is listable, in a practical and medically
appropriate sense, they get on the list. So we run a large list, and a pared down
list, and we do that to maintain a sense of connectivity and consideration of
everyone who's on our list. The problem is, the metric that you're talking about is
called the transplant rate, and it's not only determined by how many transplants
you do, it's determined by the size of your list. So if I do a hundred transplants, and
my transplant list is 100 patients long, I'm going to look like I'm less busy than
someone who maintains a list of 10 patients and does 20 transplants per year. So
it's… it’s… It's a thing that gets often manipulated, and it's not an indication of how
busy or aggressive a center is doing, but it's related to more the size of that list. It's
called a gameable statistic.” [surgeon]
Waiting Period and Receipt of Transplant
The fourth major source of selection bias identified by respondents occurs
between the waiting period and receipt of transplant phases in the patient pathway.
Here, receipt of transplant is influenced by donor organ availability and regional
competition:
“I think it depends on how easy access to organs your center has and how much
competition too for those organs you have. Because if you’re in a 250-mile
radius, and you have 10 centers in that radius, then you're competing for the
same organs across 10 centers. If instead, you were three centers in that radius
or two or one, then you have a lot of offers for your patients. And so, you can wait
until he gets sicker or you just transplant him, or you can put them on an LAS
very low, and you still will have first bid to those organs” [surgeon]
This respondent suggests that transplant centers in less competitive regions may have
more flexibility in determining which patients receive which organs, because they do not
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have to compete against other centers whose patients have higher LAS. A related
concern is that the current allocation system encourages transplant centers to list highrisk patients, but discourages centers from accepting high-risk donor organs.
Consequently, programs with primarily lower-score (lower-risk) patients are forced to
accept donor organs that were turned down by the centers with higher-score (higherrisk) patients:
“it is unfair that you can have a very high LAS score and you could decide
whatever lungs you wanna take” [surgeon].
While respondents admitted that they had no proof of higher-volume centers gaming the
system by being overly selective with which donor organs they accept, they also pointed
out that when the best-quality donor organs continually go to the highest-volume
centers, “it makes you second guess the system” [surgeon].
The above concerns suggest that there is a tension between improving the
health of individual patients versus maintaining the health of the overall transplant
program. Such tension was often described as being driven by the UNOS/CMS
accountability metrics to which programs are held:
“These regulatory metrics, 30-day, one year mortality, have a very heavy impact
on how surgeons and pulmonologists number one, list patients, it becomes a
selective bias. And number two, how they transplant them, i.e., when they get an
offer, they may be very risk adverse in certain settings or with certain donors or
with any additional confounders that are encountered at the time of the offer.”
[surgeon]
While centers can adjust their patient listing criteria and donor-organ acceptance criteria
to balance patient versus program health, the successfulness of these efforts is often
constrained by donor organ availability:
“We're handcuffed because there's no donor organs, our cohort is getting sicker
and sicker, and conditional survival based on your frailty or condition at the time
of transplant is compromised. [With a] precious resource that's in short supply,
your cohort is likely to get sicker, and the outcomes are likely to be worse, so that
the longer they sit on the list, the worse the outcomes are.” [surgeon]
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To many respondents, such donor organ scarcity implied an ethical duty to select
patients who are more likely to survive transplantation in order to ensure the responsible
stewardship of resources:
“I think we are intentionally biased to transplant patients that we think are gonna
survive…because it's a scarce resource. If you're thinking about providing a
treatment that's a scarce resource that might compromise access to other
patients, then I think it is reasonable to consider giving it to the patients where it
may be more likely to be efficacious” [surgeon].
Thus, the tension between patient and program health can also be framed as a conflict
between increasing access to care and responsible stewardship of donor organs.

Conceptual Model
Respondents identified many sources of selection bias that can arise at various
points along the pathway from referral to transplant (Figure 4.1, unshaded boxes). These
sources of selection bias were synthesized into five main concepts (Figure 4.1, shaded
boxes): 1) transplant center’s level of risk tolerance and accountability, 2)
successfulness and fairness of the LAS in mitigating selection/survivor bias, 3) patient
health versus program health, 4) donor organ availability and regional competition, and
5) access to care versus responsible stewardship of organs.
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2) Successfulness
and fairness of LAS

• Goal: determine the appropriate order in which patients should receive
donor organ offers to optimize patient’s chances of getting transplant
• LAS score ranks patients based on predicted survival with vs. without
transplant. However, the LAS:
Ø Relies on one-year survival, which may not be as relevant to patients
or clinicians as three- or five-year survival or quality of life
Ø Fails to include variables important for predicting survival among
some diagnosis groups but not others
Ø Can vary by center among patients dual-listed at multiple centers
Ø Ignores differences in listing/de-listing practices across centers

Referral à Screening/evaluation à Waitlist Registration à Waiting Period à Receipt of transplant
3) Patient health vs.
Program health

• Goal: refer potential
transplant candidates to
transplant centers for
further evaluation
Ø Patient and provider
knowledge about
transplant

• Goal: determine whether patient is a
suitable transplant candidate and
whether the program has sufficient
resources and skill to transplant them
successfully
• Decisions are influenced by:
Ø Clinician judgment and subjective
impression of patient
Ø Transplant center volume
Ø Center risk tolerance given regulatory
pressures

• Goal: optimize donor organ procurement and
quality to ensure the most appropriate donor organ
is matched with each transplant candidate
Ø Donor organ scarcity necessitates some form of
patient selection
Ø Donor organ acceptance criteria given
regulatory pressures
Ø Donor organ acceptance criteria given regional
competition

1) Transplant center’s level of risk
tolerance & accountability

4) Donor organ availability & regional competition

5) Access to care vs. Responsible stewardship of organs

Figure 4.1. Conceptual model of sources of selection bias in lung allocation
Conceptual model depicts points at which selection bias can arise in lung transplantation and
synthesizes these sources of selection bias into common themes and relationships between them.

The vast majority of these concepts were endorsed by both transplant surgeons
and pulmonologists, with one exception: issues related to donor organ screening and
procurement (including travel logistics and donor organ quality assessments) were
primarily discussed by surgeons, not pulmonologists. That is, while the overall
conceptual model holds for both pulmonologists and transplant surgeons, these two
types of respondents generally approached the discussion of selection bias in lung
transplantation from the perspective most aligned with their role in the transplant
process. Specifically, pulmonologists – who provide longitudinal patient care to particular
patients both before and after transplantation – tended to focus on “optimizing the
recipient” so that the best patient is selected for each donor organ:
“I think the main thing that we're looking to do and I'm not sure it's the LAS
number, the LAS number, or severity. I think we're certainly always looking to
maximize...I mean, maximize isn't the right word. I think we want to be sure that
the score as accurately as possible reflects the patient's severity of illness. So
whether that's updating various testing parameters periodically. It's certainly an
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awareness of the patient's underlying condition and relatively aggressive
assessment of changes to that condition in an effort to try to optimize the
allocation score” [pulmonologist]
This perspective aligns most closely with concept (2) in the model.
Conversely, transplant surgeons – who are typically responsible for procuring
donor organs in addition to performing the actual transplant procedure – tended to focus
on “optimizing the donor” so that the best donor organ is selected for each patient:
“The lung allocation score only creates the potential offer. It doesn't control the
quality of the offer. If you have a situation with a patient with a high score, who is
likely to become a candidate for a number of offers, then a lung that is marginal
may not be readily accepted. And instead, one would say, ‘Hold out for a better
organ so we have a better outcome proposition.’ But what is a better organ is in
the eye of the beholder. And there is some science, but no real class evidence or
truly binding guidelines or regulations feasible because it remains a big black
box. It's just experienced surgeons and physicians trying to extrapolate data that
helps them decide what would or wouldn't be a functional organ. Because you
want to avoid the high risk recipient with a marginal donor lung because the
combination of makes for an extremely difficult postoperative course, in the vast
majority of cases, and therefore, increases dramatically your chance of 30-day
mortality or one year mortality” [surgeon]
This perspective aligns most closely with concept (3) in the model.

Discussion
Based on this semi-structured interview study, we developed a conceptual model
(Figure 4.1) of selection bias in lung transplantation that contains five concepts. 1:
Transplant center’s level of risk tolerance and accountability. This concept captures
selection bias arising between screening and waitlist registration, where clinicians’ goal
is to determine a) whether patients are suitable transplant candidates, and b) whether
the program has sufficient resources and skill to transplant these patients successfully.
2: Successfulness/fairness of the LAS, which encompasses waitlist registration and the
waiting period. Here, the goal is to determine the appropriate order in which patients
should receive donor-organ offers to optimize their chances of transplantation. 3: Patient
versus program health, captures the tension between clinicians’ dual responsibilities of
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advocating for individual patients while maintaining the health of their overall program. 4:
Donor-organ availability and regional competition. This concept focuses on the transition
between waiting period and transplantation, where the goal is to optimize donor-organ
procurement and quality to ensure that the most appropriate donor organ is matched
with each transplant candidate. 5: Access to care versus responsible stewardship of
organs, which captures conflicts between “optimal” patient selection and “optimal” donororgan selection.
While most respondents recognized that the LAS is partially successful in
mitigating survivor bias at the point of organ allocation, many also suggested that the
LAS ignores upstream sources of selection bias (e.g., listing/de-listing) that influence
which patients are registered on the waitlist and remain active candidates. Existing
literature on upstream sources of selection bias tends to frame the problem as “access
to care” and not also an issue of “selection bias”. For example, disparities in waitlist
registration are often attributed to inequities in referrals without consideration of
inconsistencies in screening or listing decisions (which also creates inequities). Although
referral and listing guidelines exist (Weill et al., 2015), recent research has advocated for
earlier referral or multiple listing of specific patient populations (e.g., cystic fibrosis)
(Mooney, Yang, et al., 2019; Ramos et al., 2019; Stephenson et al., 2021). Others have
called for “standardized recognition and reporting of factors (e.g., frailty, social support,
quality of life) which are relevant to lung transplant patient selection but which are not
included in the formal evaluation process” (Blumenthal et al., 2017; Ladin et al., 2019;
Schaenman et al., 2020). Our respondents suggest that the extent to which these criteria
matter during listing decisions depends on each center’s transplant volume and level of
risk tolerance.
Initial research surrounding the LAS examined its impact on pre- and posttransplant survival (Egan & Edwards, 2016; Maxwell et al., 2014; Russo et al., 2011).
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Yet the LAS, by itself, simply prioritizes waitlisted patients; it does not fully address
selection bias occurring at other points along the transplantation pathway. Consequently,
transplant centers must manage their waitlist through other means (e.g., listing criteria),
while considering potential tradeoffs between patient and program health. For example,
relaxing listing criteria can provide higher-risk patients with an opportunity for transplant,
but may also necessitate greater patient management and/or donor-organ selectivity to
maximize patients’ chances of surviving surgery and minimize their risk of posttransplant complications (e.g., graft rejection) (Hart & Engels, 2021). Similarly, while
listing less-urgent patients lessens program-level risk, it may also hinder transplant
access for higher-risk patients, who might not have enough social/financial resources to
be listed at another center (Wagener, 2020).
Such findings are consistent with, and add significantly to, research on decisionmaking in organ transplant selection committees (Blumenthal et al., 2017; Volk et al.,
2011). Prior studies included few transplant surgeons and pulmonologists; focused
solely on candidate screening rather than the complete pathway from referral through
transplantation; did not examine how patients’ LAS might influence candidate selection;
and only considered patient-level factors – not program-level factors – that might
influence decision-making (Blumenthal et al., 2017; Volk et al., 2011). Our study
addresses these limitations.
Although statistical methods have been developed to address censoring among
waitlisted patients (e.g., due to death, transplantation, etc.) (Schnellinger et al., 2021;
Vock et al., 2017; Vock et al., 2013; Xiang & Murray, 2012; Xiang et al., 2014), few
studies have investigated disparities in de-listing, despite the fact that de-listing can
influence patients’ chances of transplantation and their long-term health (Rudasill et al.,
2019). Our respondents suggest that clinicians employ careful waitlist management
strategies – e.g., “substitute” waitlists –to maintain program health.
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Research centered on receipt of transplant primarily focuses on geographic
disparities in donor lung availability (Benvenuto et al., 2018; Drolen et al., 2020; RossDriscoll et al., 2020) and the role organ procurement organizations (OPOs) have in
increasing donor-organ supply through broader organ sharing (Mooney, Bhattacharya, et
al., 2019) and better procurement practices (Doby et al., 2020; Halpern et al., 2021). Yet
transplant programs ultimately have the final say over which donor organs they accept,
with some programs being more willing to accept marginal-quality/high-risk organs
(Levitsky et al., 2017; Van Pilsum Rasmussen et al., 2020; Whitford et al., 2020) than
others (Loss et al., 2013; Van Pilsum Rasmussen et al., 2019). Research on pancreas
donors in Germany concluded that the evaluation of donor organs was “highly
inconsistent” across transplant centers and that both “very cautious” and “very
permissive” acceptance criteria “may render the allocation process less efficient” (Loss
et al., 2013). For example, accepting marginal-quality donor organs can enable more
patients to receive transplant, but may come at the cost of more post-transplant
complications or reduced post-transplant survival (Schwarz et al., 2020). Such conflicts
between access to care and responsible stewardship of organs are consistent with the
findings of (Volk et al., 2011), and have both practical and ethical implications (Persad et
al., 2009; Veatch & Ross, 2015). Thus, understanding how clinicians decide which donor
organs to accept – and making this source of selection bias more transparent throughout
the transplant community – is just as important as increasing donor-organ supply.
Our study has several strengths. Rigorous qualitative analyses allowed us to
capture a diversity of perspectives on selection bias in lung transplantation and the LAS.
Including transplant surgeons and pulmonologists from transplant centers throughout the
U.S. strengthens the robustness of our conceptual model, and allowed us to understand
how center volume and location may shape screening, waitlisting, and transplantation
decisions. Finally, considering the entire pathway from referral through transplantation
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enabled us to build upon existing literature and examine how patient- and program-level
factors influence selection bias in lung transplantation.
Our study also has limitations. First, the coronavirus pandemic necessitated
switching from in-person to phone interviews midway through data collection. This
change did not impact interview quality, and actually increased surgeons’ participation
rate. Second, the qualitative design is limited in its ability to generalize to the concerns of
all transplant providers. However, we purposively sampled by discipline (transplant
surgeon, pulmonologist) and sought to include respondents with diverse characteristics
relevant to our study question (e.g., geography, years in practice). Third, although our
response rate was low we were able to obtain thematic saturation both overall and within
subgroups defined by discipline. Finally, although 84% of respondents were male, this
proportion is consistent with the distribution of men in the transplant workforce (Cooke et
al., 2019; Erhunmwunsee et al., 2019; Valbuena et al., 2021).
Overall, our study demonstrates how selection bias can arise throughout lung
transplantation, and the proposed conceptual model can facilitate further study of such
bias. Although this conceptual model was developed among lung transplant surgeons
and pulmonologists, it may be applicable to other organ allocation systems that aim to
determine which patients to register for transplant and how to prioritize them. With
respect to lung transplantation, OPTN is currently developing a new allocation
framework, the “continuous distribution model” (Kasiske et al., 2020; Snyder et al., 2018;
U.S. Department of Health & Human Services), that aims to prioritize patients via
composite scores consisting of the LAS alongside other patient attributes, such as
candidate biology, patient access, and placement efficiency (U.S. Department of Health
& Human Services). This approach is a first step toward recognizing the complex nature
of organ allocation, which requires “high performance, alignment, and accountability
from donor hospitals, OPOs, and transplant programs” (Hauerwaas & Weisenfeld, 2020;
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O'Connor & Glazier, 2021). However, our findings suggest that the other attributes
included in the composite score may be susceptible to selection bias as well. Thus, the
continuous distribution model should be monitored closely during development and
implementation to ensure that the resulting allocation scheme is more equitable and
does not inadvertently exacerbate selection bias in transplantation.
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CHAPTER 5. CONCLUSIONS
Summary of Findings
In Chapter 2 we developed a modified LAS score using inverse probability
weighting to mitigate selection bias in both the pre- and post-transplant survival models,
and demonstrated improved predictive performance of the modified LAS relative to the
existing one. Our findings suggest that the additional variables incorporated into our
weights (e.g., geography) may be important to consider when estimating pre- and posttransplant survival. Additionally, selection bias appeared to have a larger impact on the
estimate of waitlist urgency than on the estimate of post-transplant survival. Finally,
although the estimate of post-transplant survival under the modified LAS was generally
the same or greater than that under the existing LAS, the estimate of pre-transplant
survival also tends to be longer under the modified LAS. Consequently, a sizable
number of patients with intermediate scores under the existing LAS would receive lower
scores under the modified LAS.
In Chapter 3, we explored the demographic and clinical characteristics of patients
who receive better or worse priority under the modified LAS compared to the existing
LAS and investigated how the modified LAS might impact pre- and post-transplant
survival if it were implemented in clinical practice. Our findings suggest that changes in
prioritization were more pronounced for certain demographic and clinical characteristics,
such as diagnosis group, six-minute walk distance, continuous mechanical ventilation,
functional status, and age. Moreover, changes in predicted pre-transplant survival
tended to explain a greater proportion of variability in the differences in rank than did
changes in post-transplant survival. Finally, our statistical simulation study suggests that
one-year waitlist survival may improve under the modified LAS, while one-year posttransplant and overall survival remain comparable to that under the existing LAS.
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In Chapter 4, we conducted a qualitative interview study of lung transplant
surgeons and pulmonologists throughout the United States to understand how they
perceive the LAS and selection bias. Our findings suggest that selection bias can arise
at several points along the transplantation pathway, and that these sources of selection
bias can be synthesized into five factors: 1) transplant center’s level of risk tolerance and
accountability, 2) successfulness and fairness of the LAS in mitigating selection bias, 3)
donor organ availability and regional competition, 4) patient health versus program
health, and 5) access to care versus responsible stewardship of organs.

Benefit of Incorporating Quantitative and Qualitative Objectives
While we presented our quantitative and qualitative objectives sequentially, they
very much worked in parallel, informing each other. For example, findings from our
qualitative study encouraged us to expand the focus of our quantitative study from
survivor bias specifically to selection bias more generally. Similarly, our quantitative
finding that selection bias had a greater impact on waitlist urgency than on posttransplant survival is consistent with some interview respondents’ comments suggesting
that upstream sources of selection bias (e.g., referral and listing) may be more clinically
relevant than downstream ones (e.g., donor organ acceptance criteria). Thus, by
incorporating both quantitative and qualitative research into this dissertation, we were
able to develop a more comprehensive and nuanced understanding of selection bias
and its impact in lung allocation.

Selection versus Selection-Bias
Throughout our interviews, some respondents raised concerns about the phrases
“selection bias” and “survivor bias”, pointing out that some form of patient selection is
often necessary in the face of donor organ scarcity and accountability-promoting
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regulatory pressures. Since a considerable component of patient selection is based on
subjective clinical judgment, some respondents emphasized the importance of including
a wide variety of perspectives in their selection committees to ensure that patient
selection occurs in a fair manner. Other respondents acknowledged the enormity of the
decisions being made in the presence of imperfect and incomplete information. Taken
together, these comments highlight how the epidemiologic notion of selection bias (and
its removal) does not always agree with the clinical notion of selection (and its
necessity). These differences in perspectives on “good” versus “bad” selection bias will
be important to consider when designing and developing new allocation frameworks,
such as the continuous distribution model (Kasiske et al., 2020; Snyder et al., 2018; U.S.
Department of Health & Human Services).

Limitations
The studies undertaken in this dissertation are not without limitations. First, when
developing our proposed modified LAS (Chapter 2), insufficient information was
available to consistently distinguish between patients who were newly listed and those
who were re-activated after temporary waitlist removal. Thus, the first record associated
with each identification number was taken to be the initial registration date, follow-up
time was counted from that date forward, and individuals who were subsequently lost to
follow-up were censored at that time. Given that only about 1.25% of registered
individuals in our dataset were lost to follow-up prior to transplantation, this analytic
decision is unlikely to influence our results. However, future studies could consider
including variables indicating whether patients are currently active or inactive on the
waitlist, how many times they transition to and from the active and inactive states, and
the frequency of their visits to the transplant center to better capture their waitlist history
and disease trajectory.
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Another limitation of our modified LAS is that we developed it after excluding
individuals on the waitlist who were highly unlikely to receive transplant due to certain
patient characteristics (e.g., high sensitization or small stature) that prevent them from
finding a suitable donor organ match. This exclusion was necessary to ensure that we
fulfill the positivity assumption of IPTW & IPCW weighting – that is, to ensure that all
individuals have at least some non-zero probability of receiving transplant. However, it
also implies that we cannot generalize our findings to patients who have these clinical
contraindications. Although the proportion of individuals excluded under this criteria was
small (i.e., 1.79%) and unlikely to influence our results, future work should explore how
we might mitigate selection bias among patients with these clinical contraindications. For
example, we could build off of recent research on population decomposition by
decomposing our study population into several groups: 1) those who survive and receive
transplant, 2) those who die prior to transplant, and 3) those who survive indefinitely
without receiving transplant (i.e., the individuals with clinical contraindications who were
excluded from our study); then, we could fit a separate regression model among each
subgroup and re-weight our outcome models based on the inverse of the joint probability
of each subgroup-specific regression model (Haneuse & Daniels, 2016).
A third limitation of our quantitative study is that we cannot account for the fact
that presence in the UNOS database is not random, but rather indicates that the patient
was ill enough to visit the hospital, undergo evaluation for transplant, and be registered
on the waitlist. Consequently, selection bias associated with waitlist registration can still
affect predicted mortality. Future work should strive to collect referral data so that we can
mitigate this additional source of selection bias.
Our assessment of the clinical impact of the modified LAS versus the existing
LAS (Chapter 3) has some limitations as well. First, the generalized linear mixed model
(GLMM) approach we took to estimate the proportion of variability (r2) in the differences
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in rank explained by changes in predicted pre- versus post-transplant survival does not
account for the correlation among differences in rank. We mitigated this issue by splitting
the data into worse-priority and better-priority subsets, and fitting separate GLMMs to
each subset. However, future methodologic research is needed to extend generalized r2
statistics to the situation where the outcome of interest is differences in ranks.
Second, while we used the observed testing cohort data to compare the order in
which patients were prioritized under the two models and examine the clinical
characteristics of patients who received better or worse priority under the modified LAS
relative to the existing LAS, we cannot know whether patients who died on the waiting
list under the existing LAS would, in fact, have received transplant had the modified LAS
been used instead. This limitation motivated us to conduct the pilot simulation study
described in Chapter 3, where we examined how patients’ waitlist and post-transplant
survival might change if the modified LAS were implemented in clinical practice.
However, this simulation was limited in scope, assuming an artificially simple allocation
policy based on blood type and region only (i.e., ignoring other salient factors to organ
matching, such as donor/recipient size and sensitization, donor organ quality and
acceptance criteria, and travel constraints that arise when delivering donor organs to
transplant candidates). Future work should aim to incorporate these additional factors
into the simulation to see how the modified LAS might perform in more realistic settings.
With regards to our qualitative study (Chapter 4), the conceptual model we
developed aims to describe how and when selection bias can arise in transplantation
and the LAS. Although we sought to capture a diversity of perspectives on the LAS by
sampling purposively by discipline (lung transplant surgeon, pulmonologist) and by
including respondents from a variety of geographic regions with different amounts of
experience (years in practice), we cannot generalize our findings to the concerns of all
transplant providers. To the extent that transplant decisions are not made solely by lung
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transplant surgeons and pulmonologists, future studies should consider interviewing
patients or other providers (e.g., referring physicians, transplant nurses, and social
workers) to understand their perspectives on selection bias in transplantation. Such an
approach could inform the design of interventions aimed at improving referral rates and
decreasing loss to follow-up.

Future Directions
The findings from our studies highlight the importance of recognizing and
addressing selection bias throughout the transplantation process and are applicable to
other organ allocation systems which rely on estimates of pre- and/or post-transplant
survival to prioritize patients, such as the United States’ Estimated Post-Transplant
Survival (EPTS) score for kidney allocation (Egan et al., 2006; Organ Procurement and
Transplantation Network, 2020; Veatch & Ross, 2015), Germany’s lung allocation score
(Gottlieb, 2017; Gottlieb et al., 2014), and the United Kingdom’s Liver Transplant Benefit
Score (NHS Blood and Transplant). Findings from our study could also inform the
development of pre- and post-transplant survival models for organs which do not yet use
such models to guide allocation decisions. This step will become important as other
organs begin to adopt the continuous distribution allocation framework (Kasiske et al.,
2020; Snyder et al., 2018; U.S. Department of Health & Human Services). Assessments
of time-dependent discrimination and calibration for both the existing LAS and the
modified LAS (Chapter 2) are relevant here as well, especially as the transplant
community considers what role longer-term survival should play in organ allocation
(Kasiske et al., 2020; Maxwell et al., 2014; U.S. Department of Health & Human
Services).
Our pilot simulation (Chapter 3) provides preliminary evidence of how waitlist and
post-transplant survival might change if the modified LAS were implemented in clinical
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practice. However, as mentioned above, this simulation was limited in scope, ignoring
many factors that are relevant to organ allocation and donor-recipient matching. In
addition to incorporating these factors into the simulation, future work should also aim to
provide more flexibility in terms of which simulation parameters can be varied (e.g.,
allowing the user to specify alternative scoring systems or geographic sharing rules).
This approach would enable researchers to test a variety of allocation policy changes
and evaluate their impact on a hypothetical (simulated) population before deciding
whether to implement such policies in clinical practice.
Our conceptual model (Chapter 4) can also inform the development of new
allocation systems, such as the continuous distribution model. Specific attention should
be paid to sources of selection bias outside of the LAS, such as referral, listing/de-listing
decisions, and donor organ acceptance criteria. These “external” sources are especially
important to consider in the context of the continuous distribution model, which aims to
combine the components of the LAS (i.e., pre- and post-transplant survival) with other
attributes – such as candidate biology (e.g., blood type, sensitization, height), patient
access (e.g., increase access for individuals under age 18 and for prior living donors),
and placement efficiency (e.g., distance from donor hospital and travel efficiency) – in a
weighted average composite score (Kasiske et al., 2020; Snyder et al., 2018; U.S.
Department of Health & Human Services). While the goal of this composite score is to
minimize situations where certain individuals are given absolute priority over other
“clinically similar” individuals (U.S. Department of Health & Human Services) (e.g.,
because they happen to have a particular clinical characteristic which drives their LAS
score), findings from our study suggest that the other attributes included in the new
composite score can be susceptible to selection bias as well. Thus, the development,
implementation, and performance of the continuous distribution model should be
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monitored closely to ensure that it does not inadvertently exacerbate selection bias in
transplantation.

Concluding Remarks
Collectively, the findings from this dissertation suggest that selection bias is
important to address throughout the transplantation process. We hope that these
findings, as well as our recommendations for future research, can inform future revisions
of the LAS and other prediction models in organ transplantation to improve prediction of
pre- and post-transplant survival, mitigate selection biases at other points in the
transplantation pathway, and ensure more equitable allocation of donor organs.
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APPENDIX

Appendix 2.1. Weight Truncation
To minimize the impact of extreme weights on our outcome models, we
progressively truncated the final pre- and post-transplant weights following the
procedure outlined in (Cole & Hernán, 2008). More specifically, we replaced weights that
were below (above) a certain percentile with the value at that percentile. By
progressively increasing (decreasing) the percentiles from 0% (100%) to 5% (95%), we
could explore the trade-off between bias and variance. Appendix Table 2.1 displays the
distribution of the pre-transplant weights, alternatively-stabilized pre-transplant weights
(i.e., those used to construct the post-transplant weights; see main text for details), and
post-transplant weights under various truncation percentiles. As the extent of truncation
increases, the mean of the weights moves further away from one, indicating a greater
degree of bias; conversely, the variance of the weights moves closer to zero, suggesting
greater precision. Ultimately, the final weights were truncated at the 0.25% (99.75%)
percentiles, as these were the ones which centered the weights around one and which
reduced the 1/minimum and maximum weights by at least one order of magnitude (Cole
& Hernán, 2008).
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Appendix Table 2.1. Distribution of pre- and post-transplant weights under various truncation
percentiles
The distribution of the final weights appears in bold.

Appendix Table 2.1A) Distribution of pre-transplant weights
Truncation Percentiles
0, 100
0.25, 99.75
0.5, 99.5
1, 99
2.5, 97.5
3.5, 96.5
5, 95

Mean
1.127
1.034
1.024
1.006
0.976
0.962
0.948

Variance
26.91
0.817
0.666
0.485
0.316
0.265
0.223

Minimum
1.28E-09
0.001
0.003
0.010
0.042
0.069
0.113

Maximum
551.0
10.29
7.386
4.832
2.902
2.396
2.025

Appendix Table 2.1B) Distribution of alternatively-stabilized pre-transplant weights
Truncation Percentiles
0, 100
0.25, 99.75
0.5, 99.5
1, 99
2.5, 97.5
3.5, 96.5
5, 95

Mean
1.148
0.959
0.941
0.915
0.871
0.856
0.839

Variance
530.7
1.492
1.080
0.729
0.427
0.370
0.316

Minimum
9.81E-05
0.001
0.001
0.003
0.011
0.017
0.028

Maximum
1.01E+04
14.88
9.656
6.020
3.070
2.572
2.147

Minimum
1.50E-04
0.009
0.023
0.033
0.059
0.077
0.103

Maximum
599.8
17.09
9.531
4.948
2.969
2.503
2.099

Appendix Table 2.1C) Distribution of post-transplant weights
Truncation Percentiles
0, 100
0.25, 99.75
0.5, 99.5
1, 99
2.5, 97.5
3.5, 96.5
5, 95

Mean
1.175
0.962
0.936
0.905
0.875
0.862
0.847

Variance
75.33
1.625
0.998
0.621
0.445
0.394
0.345
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Appendix 2.2. Baseline Survival Probabilities for Modified Outcome Models
In this section, we display the baseline survival probabilities (Appendix Table 2.2)
obtained from the modified (weighted) pre- and post-transplant outcome models. These
survival probabilities were used in conjunction with the parameter estimates shown in
Table 2.3 in Chapter 2 to construct modified LAS scores for patients in our testing
cohort.
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Appendix Table 2.2. Baseline survival probabilities for the modified pre- and post-transplant LAS
Appendix Table 2.2A) Baseline survival probabilities for the modified pre-transplant outcome model
Time
(days)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

Waitlist
Survival
1.00000000
0.99949890
0.99861080
0.99847020
0.99824380
0.99809990
0.99787550
0.99771830
0.99762050
0.99752650
0.99738530
0.99721320
0.99715210
0.99700950
0.99690890
0.99680770
0.99673020
0.99669440
0.99663090
0.99651170
0.99637040
0.99633550
0.99630000
0.99622360
0.99618820
0.99607970
0.99606270
0.99595380
0.99588110
0.99580880
0.99580880
0.99575660
0.99575660
0.99555590
0.99543440
0.99535690
0.99529670
0.99504970
0.99498210
0.99482720
0.99478720
0.99470050
0.99467110
0.99464450
0.99457450
0.99455430
0.99449440
0.99449440
0.99439620
0.99436790
0.99429490
0.99427350
0.99413210
0.99409040
0.99397610
0.99387900
0.99387900
0.99361910
0.99361910

59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119

0.99353570
0.99351250
0.99343780
0.99334730
0.99327860
0.99303570
0.99298630
0.99294020
0.99294020
0.99278280
0.99270620
0.99225440
0.99217070
0.99211770
0.99205410
0.99195170
0.99192470
0.99188070
0.99188070
0.99183380
0.99180110
0.99174440
0.99174440
0.99171980
0.99169260
0.99169260
0.99165900
0.99161170
0.99157360
0.99144450
0.99127280
0.99127280
0.99127280
0.99123600
0.99105800
0.99097330
0.99069050
0.99065850
0.99057640
0.99057640
0.99057640
0.99057640
0.99057640
0.99050870
0.99045280
0.99045280
0.99042720
0.99032910
0.99032910
0.99032910
0.99032910
0.99028200
0.99028200
0.99025570
0.99022540
0.99015130
0.99009470
0.99009470
0.99009470
0.99009470
0.99004220
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120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180

0.98999600
0.98999600
0.98990010
0.98990010
0.98987070
0.98987070
0.98979010
0.98975310
0.98970750
0.98957860
0.98945660
0.98945660
0.98945660
0.98938810
0.98927390
0.98927390
0.98924580
0.98924580
0.98924580
0.98901980
0.98898180
0.98898180
0.98891120
0.98881060
0.98881060
0.98881060
0.98862540
0.98862540
0.98859800
0.98859800
0.98855410
0.98855410
0.98850870
0.98846440
0.98846440
0.98838650
0.98833870
0.98833870
0.98833870
0.98828630
0.98828630
0.98810580
0.98810580
0.98807000
0.98807000
0.98804610
0.98799710
0.98799710
0.98799710
0.98799710
0.98792760
0.98789130
0.98784470
0.98784470
0.98778040
0.98778040
0.98762660
0.98752250
0.98752250
0.98752250
0.98752250

181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242

0.98747760
0.98686000
0.98643590
0.98606400
0.98558710
0.98555720
0.98547530
0.98542620
0.98535930
0.98530210
0.98530210
0.98530210
0.98517610
0.98517610
0.98517610
0.98517610
0.98498220
0.98489450
0.98480400
0.98465610
0.98465610
0.98465610
0.98457030
0.98457030
0.98457030
0.98452710
0.98444500
0.98444500
0.98440380
0.98440380
0.98440380
0.98440380
0.98440380
0.98422070
0.98422070
0.98406430
0.98406430
0.98406430
0.98398360
0.98398360
0.98398360
0.98398360
0.98398360
0.98392360
0.98384980
0.98378170
0.98378170
0.98378170
0.98353850
0.98353850
0.98329040
0.98317210
0.98310490
0.98304650
0.98304650
0.98304650
0.98304650
0.98300730
0.98295540
0.98242220
0.98236150
0.98229290

243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304

0.98229290
0.98229290
0.98229290
0.98229290
0.98229290
0.98217620
0.98217620
0.98217620
0.98202600
0.98202600
0.98202600
0.98202600
0.98202600
0.98195530
0.98185160
0.98185160
0.98176630
0.98176630
0.98139880
0.98131640
0.98125940
0.98125940
0.98125940
0.98104180
0.98090980
0.98080010
0.98080010
0.98039670
0.98032500
0.98032500
0.98032500
0.98032500
0.98032500
0.98021850
0.98001860
0.98001860
0.97993420
0.97993420
0.97985390
0.97985390
0.97985390
0.97985390
0.97985390
0.97985390
0.97985390
0.97976220
0.97976220
0.97976220
0.97976220
0.97975350
0.97975350
0.97963670
0.97954550
0.97954550
0.97954550
0.97939460
0.97930350
0.97930350
0.97930350
0.97920520
0.97912270
0.97912270
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305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364

0.97912270
0.97908000
0.97908000
0.97908000
0.97908000
0.97908000
0.97896840
0.97896840
0.97896840
0.97896840
0.97896840
0.97896840
0.97894650
0.97894650
0.97881190
0.97881190
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97874950
0.97868070
0.97868070
0.97868070
0.97868070
0.97854430
0.97848880
0.97848880
0.97807370
0.97807370
0.97807370
0.97801020
0.97766270
0.97766270
0.97766270
0.97766270
0.97761010
0.97761010
0.97761010
0.97761010
0.97758430
0.97737180
0.97737180
0.97737180
0.97721110
0.97721110
0.97721110
0.97721110
0.97705880
0.97705880
0.97705880
0.97705880
0.97705880

Appendix Table 2.2B) Baseline survival probabilities for the modified post-transplant outcome model
Time
(days)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

Post-transplant
Survival
0.998379000
0.996209000
0.995379400
0.994953900
0.993997900
0.992298200
0.991685700
0.991396500
0.991039700
0.990595300
0.989299400
0.988702900
0.987841900
0.987356600
0.987100000
0.986487900
0.986323600
0.986016400
0.985647500
0.985276200
0.984772100
0.984616200
0.984040200
0.983644800
0.982689800
0.981989400
0.980997600
0.980587300
0.980077000
0.979670700
0.979599900
0.979448300
0.979286400
0.979130000
0.978923600
0.978855600
0.978692100
0.978400000
0.978172400
0.977904100
0.977776900
0.977734100
0.977639500
0.977488500
0.977392400
0.977168300
0.977003700
0.976958500
0.976732100
0.976600200
0.976471600
0.976109700
0.976018100
0.975722700
0.974344400
0.973900600
0.973895700
0.973762800
0.973460100
0.973216100
0.973103000
0.973052600

62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125

0.972896600
0.972679700
0.972528200
0.972342200
0.972271300
0.972008500
0.971873800
0.971872000
0.971683500
0.971650800
0.970162600
0.970044900
0.969789700
0.969757400
0.969443500
0.969000000
0.968453000
0.967538600
0.967524800
0.967168700
0.966833000
0.966816600
0.966757400
0.966510500
0.966219100
0.965916700
0.965883700
0.965768100
0.965748000
0.965563800
0.965503500
0.965338700
0.965007600
0.964726900
0.964699200
0.964074500
0.963914900
0.963844300
0.963640400
0.963522400
0.963408300
0.963045300
0.962898400
0.962898400
0.962100800
0.962046800
0.962046800
0.961838900
0.961772900
0.961755900
0.961686100
0.961529700
0.961294400
0.961167500
0.961068800
0.961046200
0.960706400
0.960585500
0.960303000
0.960256100
0.960174400
0.959945900
0.959896700
0.959729300
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126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189

0.959527900
0.959465300
0.958906800
0.958779200
0.957531500
0.957405300
0.957405300
0.957353700
0.957239700
0.957239700
0.957233100
0.957141500
0.957141500
0.957070300
0.956980500
0.956749500
0.956740300
0.956274000
0.956183900
0.956071300
0.955805500
0.955735200
0.955626400
0.955425500
0.955280800
0.955147300
0.955049300
0.954756700
0.954693900
0.954568900
0.954542000
0.954471600
0.954321000
0.954193400
0.954054100
0.954054100
0.953888700
0.953675300
0.953573600
0.953506300
0.953472300
0.953452700
0.953325100
0.953237900
0.953237900
0.952996100
0.952936600
0.952710200
0.952282200
0.952176300
0.952116600
0.952017100
0.951952000
0.951952000
0.951952000
0.951950000
0.951911600
0.951601600
0.951466600
0.951463200
0.951400900
0.951214000
0.951092900
0.950993600

190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248

0.950847200
0.950584600
0.950504200
0.950463300
0.950147200
0.950147200
0.949776700
0.949665600
0.949574900
0.949529500
0.949529500
0.949463900
0.949422900
0.949243500
0.949027900
0.948980500
0.948826800
0.948815700
0.948689100
0.948545700
0.948230000
0.948183900
0.948036900
0.947931400
0.947726400
0.947523600
0.947122800
0.946956200
0.946857200
0.946711000
0.946613100
0.946086500
0.945987800
0.945961600
0.945961600
0.945942200
0.945703000
0.945703000
0.945670900
0.945435400
0.945435400
0.945277600
0.945208200
0.945014400
0.944705400
0.944600100
0.944469400
0.944377700
0.944296600
0.944296600
0.943992600
0.943724900
0.943714900
0.943588400
0.943588400
0.943468900
0.943468900
0.943394300
0.943310700

249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307

0.943023900
0.942614300
0.942614300
0.942598800
0.942598800
0.942598800
0.942313600
0.942255900
0.942201500
0.942201500
0.942201500
0.941973900
0.941789600
0.941781600
0.941551900
0.941510100
0.941169200
0.941169200
0.940625100
0.940375000
0.940290800
0.940290800
0.940124700
0.939783100
0.939713600
0.939536700
0.939360300
0.939360300
0.939224500
0.939219000
0.939219000
0.939210000
0.938749000
0.938478000
0.938264200
0.937949200
0.937949200
0.937933700
0.937672600
0.937491100
0.937464300
0.937374400
0.937180800
0.937130700
0.936952600
0.936940400
0.936704100
0.936677300
0.936576600
0.936576600
0.936544200
0.936416600
0.936385300
0.936285700
0.936217100
0.936217100
0.936097700
0.936017000
0.935961000
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308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364

0.935924900
0.935584800
0.935510100
0.935276100
0.935252500
0.935242800
0.935242800
0.935234600
0.935234600
0.935234600
0.935081600
0.935081600
0.935081600
0.934945400
0.934927100
0.934898800
0.934809200
0.934624700
0.934624700
0.934587700
0.934535600
0.934449000
0.934449000
0.934414200
0.934267800
0.933950700
0.933911100
0.933706200
0.933689000
0.933689000
0.933604400
0.933426600
0.933280600
0.933167000
0.932964300
0.932928200
0.932928200
0.932928200
0.932729000
0.932729000
0.932472400
0.932472400
0.932273800
0.932266900
0.932266900
0.932230800
0.932166200
0.932071200
0.931930800
0.931914700
0.931643900
0.931368300
0.931017800
0.931009700
0.931009700
0.930992900
0.930986600

Appendix 3.1. Histograms of differences in rank
Here, we display histograms of the difference in patients’ rank under the modified
versus existing LAS for individuals receiving worse or better priority (Appendix Figure
3.1). Both cumulative change in rank and average change in rank per day are shown.
Appendix Figure 3.1. Histograms of differences in rank (overall)
Histograms of the difference in patients’ rank under the modified versus existing LAS for the subset
of individuals receiving A) lower (worse) priority, or B) higher (better) priority. Solid red line
indicates the mean shift in rank, while dotted red line represents the median shift in rank. Left
column represents change in rank across all offer dates (cumulative change in rank); right column
represents average change in rank per day.
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We also plot differences in rank after stratifying by diagnosis group (Appendix Figure
3.2) and six-minute walk distance (Appendix Figure 3.3), two clinical characteristics that
were shown in Chapter 3 to exhibit the largest impact on prioritization changes.
Appendix Figure 3.2. Histograms of differences in rank (stratified by diagnosis group)
Histograms of the difference in patients’ rank under the modified versus existing LAS for the subset
of individuals receiving A) lower (worse) priority or B) higher (better) priority, stratified by diagnosis
group. Solid red line indicates the mean shift in rank, while dotted red line represents the median
shift in rank. Left column represents change in rank across all offer dates (cumulative change in
rank); right column represents average change in rank per day.
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Appendix Figure 3.3. Histograms of differences in rank (stratified by six-minute walk distance)
Histograms of the difference in patients’ rank under the modified versus existing LAS for the subset
of individuals receiving A) lower (worse) priority or B) higher (better) priority, stratified by six-minute
walk distance. Solid red line indicates the mean shift in rank, while dotted red line represents the
median shift in rank. Left column represents change in rank across all offer dates (cumulative
change in rank); right column represents average change in rank per day.
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Appendix 4.1. COREQ Checklist
In this section, we present additional supporting information that fulfills the
requirements outlined in the Consolidated Criteria for Reporting Qualitative Research
(COREQ) checklist.(Tong et al., 2007)

Characteristics of Research Team
EMS (female epidemiologist and PhD candidate trained in qualitative data
collection and analyses) conducted the semi-structured in-person or telephone
interviews between June 2019 and June 2020. JES (female sociologist, PhD, with
mixed-methodology expertise) provided training and mentorship in data collection and
analyses. EC (male lung transplant surgeon, MD, MSCE) provided clinical expertise to
aid the construction of the interview guide and subsequent analyses. SEK (male
epidemiologist, MD, MSCE) supervised the team.

Relationship with Participants
A relationship with participants was not established prior to study
commencement. Individuals were recruited to participate in our study through the
“Pulmonology and Cardiothoracic/vascular surgery” listserv of the International Society
for Heart and Lung Transplant (ISHLT). Potential participants were informed by email of
the researchers’ and interviewer’s occupation, credentials, and training, as well as the
goals for conducting the research.

Interviews & Setting
Interviews were conducted in-person or via phone by the lead author using a
semi-structured guide (supporting information). In-person interviews occurred in the
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respondents’ office. Phone interviews were conducted from the interviewer’s office. In all
cases, no one else was present besides the participants and researchers. Each
respondent was interviewed once. Interviews typically lasted 30-50 minutes. Transcripts
were not returned to participants for feedback.

Codebook
Appendix Table 4.1 below displays our index codebook. After applying this
codebook to all transcripts in a line-by-line manner, we examined overlapping codes and
charted data into a framework matrix to compare themes within and across respondents.
Appendix Table 4.1. Index codebook
Code Name

Description

01. motivation to work in lung
transplant

Used to capture respondent's rationale for pursuing a career in lung
transplantation.

02. region – compare/contrast

Includes descriptions where respondents explicitly compare and contrast
practices at one institution/region vs. another

03. institution lung transplant
decision process

High-level description of the lung transplant decision-making process at the
respondent's institution, including information on other individuals involved in
the decision

04. pre-consultation - approach

Details on how the respondent approaches surgical/pulmonology
consultation conversations, including important factors the respondent
considers when making treatment recommendations to the patient

05. consultation - conversation
with patients

Details on what is discussed with patients during the surgical/pulmonology
consultation conversation, including information on the LAS and how patients
respond to it.

06. post-consultation - next
steps

Details on how respondent proceeds after determining that a patient should
pursue transplantation, including how the LAS influences these next steps

07. accountability

Information on how transplant centers are rated, how these ratings influence
the respondent's decision to pursue transplant for a particular patient, and
how/whether these rating metrics conflict with a patient's LAS

08. satisfaction with the LAS

How satisfied is the respondent with the way the current LAS prioritizes
patients for lung transplantation?

09. fairness of allocation

How successful (or unsuccessful) does the respondent perceive the LAS to
be in allocating donor lungs to patients in a fair manner?
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Code Name

Description

10. factors to add to LAS

Additional factors which the respondent believes should be included in the
LAS, and their rationale for inclusion.

11. gaming

Includes the respondent's thoughts on whether variables in the LAS can be
"adjusted/modified" to ensure that patients receive a more favorable position
on the waitlist, as well as if they have encountered this practice. Can also
include information on whether the procedures used to measure modifiable
variables are standardized across institutions.

12. appeals

Includes information on the UNOS appeals process, or other avenues
through which clinicians can ensure their patients receive higher LAS scores.

13. audits

Includes information on the UNOS audit process, as well as whether this
process curbs the practice of gaming.

14. characteristics of patients
who die or survive

This code is used to capture whether the respondent has an intuitive sense
of which patients might die prior to transplantation, and if so, which
characteristics distinguish patients who die from those who survive long
enough to receive transplant

15. survivor bias concern

Indicates whether the respondent thinks survivor bias is a concern in lung
transplantation, and if so, how.

16. accounting for survivor bias

Indicates whether the respondent thinks survivor bias should be accounted
for in lung transplantation, and if so, how.

17. complicating the LAS

Used to capture the respondents' thoughts on how a model which accounts
for (survivor) bias might affect the decisions they make regarding the care of
their patients. Can also include general thoughts on whether a more
complicated - but more accurate - LAS would influence the way in which the
respondent uses the model in practice.

18. if respondents were in
charge of allocation

If respondents were in charge of allocating donor lungs to potential
recipients, how would they go about doing it?

19. incredibly interesting, but
not sure how to label it

Used to capture random comments which are incredibly interesting but don't
necessarily answer any of our questions.
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Appendix 4.2. Interview Guide
The semi-structured interview guide was developed by EMS based on literature review
and discussion with the other authors. Participants were asked all questions, with
additional probing when needed. While the domains of the guide are identical for lung
transplant surgeons and pulmonologists, the specific wording of some questions vary
slightly due to the fact that these two types of clinicians play different roles in the lung
transplant decision-making process. These discrepancies are noted when applicable.
A.

Individual and organizational characteristics
i. What motivated you to work in the field of lung transplantation?
ii. How many years of experience have you had in this field?
iii. In what region do you practice?
iv. Have you ever practiced in a different institution or different region?
a) If YES, which institution/region?
v. How are decisions made about lung transplantation in your institution? Walk me
through the process from the initial patient visit, through the decision to register them
on the waiting list, through the decision to transplant. [Can you provide me with an
example?]
a) Are there other people involved in this decision? If so:
1. Who are they?
2. How would you describe your interactions with these people?

B.

Attitudes regarding end-stage lung disease treatment
i. How do you approach [surgical/pulmonology] consultations for adults with end-stage
lung disease? What factors are important to you when working up the patient and
making recommendations for their treatment?

C.

Decision to pursue lung transplantation
i. Can you explain to me the general components of a [surgical/pulmonology]
consultation conversation with adult patients with end-stage lung disease?
a) What things are discussed?
b) Do you bring up the LAS in this discussion?
c) If YES, how do you bring it up? How do patients react to it?
d) Can you explain your rationale for discussing it/not discussing it?
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ii. If you decide that a patient should pursue transplantation, how do you proceed? How
does the LAS influence these next steps if it does at all? [Use below probes if
necessary]:
a) How might the patient’s LAS influence whether you refer the patient to see a
[surgeon/pulmonologist]?
b) How might the patient’s LAS influence the way in which you present the patient
to the Lung Listing Conference?
iii. Transplant centers are often rated based on the number of transplants they perform
and their patients’ average 30-day and 1-year post-transplant mortality rates. How do
these metrics influence your decision to pursue transplant for a particular patient?
a) Have you encountered a scenario where the decision to pursue transplant is
different depending on whether these metrics or the LAS is used? If so, how do
you go about resolving the issue?
D.

Satisfaction with current LAS
i. How satisfied are you with the LAS (e.g., the way in which the current LAS prioritizes
patients for lung transplantation)?
a) What factors make you feel this way?
b) How do these feelings influence the way in which you use the LAS to make
treatment decisions?
ii. The goal of the LAS is to allocate donor lungs – a scarce resource – to patients with
chronic lung conditions in a fair manner. How successful (or unsuccessful) do you
perceive the LAS to be in accomplishing this goal? Can you explain to me why you
feel this way?
iii. Are there certain factors which you believe should be included in the LAS, but which
are not in the current model? Can you explain why you think these factors should be
included?
iv. We have heard that several variables in the LAS are modifiable, and can be adjusted
to ensure that patients receive a more favorable position on the waiting list. Have you
witnessed this? What are your thoughts on this?
a) If YES, how does this influence the way in which you use the LAS to make
treatment decisions?
b) If NO, how does this influence the way in which you perceive the LAS?
c) Are the procedures used to measure modifiable variables standardized across
institutions?
v. We have also heard that transplant programs can submit an appeal to UNOS if they
feel a particular patient should receive a higher LAS score. Have you participated in
such an appeal before? Can you explain what the appeal process is like?
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E.

Understanding of survivor bias
i. In your experience, have you noticed that certain patients die while on the UNOS
lung transplant waiting list, while others survive long enough to receive transplant?
a) What characteristics distinguish these two groups of people?
b) Do you have an intuitive sense of which patients might die prior to
transplantation?
1. If YES, how does that affect your decision to place patients on the waiting
list?
ii. In epidemiology, “survivor bias” is the idea that if treatments are offered to patients
conditional on their survival, the resulting estimate of the effectiveness of treatment
might be inaccurate. My team believes that survivor bias might play a role when
predicting outcomes of lung transplant, because in order to receive a transplant,
patients must survive long enough for a suitable donor lung to become available.
a) Do you think survivor bias might be a concern in lung transplantation? In what
way?

F.

Thoughts regarding modification of the LAS
i. Do you think survivor bias should be accounted for in the allocation of donor lungs?
a) If YES, how?
b) If NO, why do you feel that way?
ii. Adjusting for survivor bias in the LAS is possible, but it could lead to a more
complicated allocation algorithm.
a) How would having a more complicated – but more accurate – LAS model
influence the way in which you use this model in clinical practice?
b) How might it affect the decisions you make regarding the care of patients with
end-stage lung disease?
iii. If you were in charge of allocating donor lungs to potential recipients, how would you
go about doing it?

G.

Demographic Questions
i. How would you report your gender?
ii. How would you report your race/ethnicity?
iii. Where did you complete your medical training?
a) What year did you graduate?
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